Tethered Counterion-Directed Catalysis: Merging the Chiral Ion-pairing and Bifunctional Ligand Strategies in Enantioselective Gold(I) Catalysis

Zhenhao Zhang,^{a,b} Vitalii Smal,^a Pascal Retailleau, ^a Arnaud Voituriez,^a Gilles Frison,^b Angela Marinetti,^{*,a} Xavier Guinchard^{*,a}

^a Institut de Chimie des Substances Naturelles, CNRS UPR 2301, Université Paris-Sud, Université Paris-Saclay, 1 avenue de la Terrasse, 91198 Gif-sur-Yvette, France.

^b LCM, CNRS, Ecole Polytechnique, Institut Polytechnique de Paris, 91128 Palaiseau, France.

Corresponding Authors

angela.marinetti@cnrs.fr xavier.guinchard@cnrs.fr

Table of Contents

| 1. General methods | 2 |
|--|---------------|
| 2. Synthesis and Characterization of the gold(I) complexes (S)-5, (S)-6, (S)-7 and (S)-11a | 2 |
| 3. Synthesis of enones 8 and indole 9 | 11 |
| 4. Investigation with respect to the protocol for the activation of the catalysts 5 and SI-2 a | nd the silver |
| salts used | 17 |
| 5. Scope of the reaction | 18 |
| 6. X-ray Crystallography | 32 |
| 7. HPLC traces | 36 |
| 8. Copies of NMR Spectra | 61 |

1. General methods.

Unless otherwise noted, all of the reactions were performed under N₂ atomosphere, the solvents were distilled under N₂, and the separations were carried out under flash-chromatographic conditions on silica gel (Redi Sep prepacked column, 230-400 mesh) with use of a CombiFlash Companion. Reagent-grade chemicals were obtained from diverse commercial suppliers (Sigma-Aldrich, Acros Organics, TCI and Alfa-Aesar) and were used as received. n-BuLi was used as commercially available solutions and titrated before use. ¹H NMR (300 and 500 MHz), ³¹P (120 MHz and 200 MHz) and ¹³C (75 and 125 MHz) NMR spectra were recorded on Bruker Advance spectrometers. The chemical shifts (δ) are reported in part per million (ppm) and coupling values (J) are given in hertz (Hz). Multiplicities are abbreviated as follows: s (singlet), d (doublet), t (triplet), q (quadruplet), bs (broad singlet) dd (doublet of doublet), dt (doublet of triplet), m (multiplet). Infrared spectra (IR) were recorded on a Perkin-Elmer FT-IR system using diamond window Dura SamplIR II and the data are reported in reciprocal centimeters (cm-1). Optical rotations were measured on a Anton Paar MCP 300 polarimeter at 589 nm. $[\alpha]_D$ is expressed in deg.cm³.g⁻¹.dm⁻¹ and c is expressed in g/100 cm³. Melting points were recorded in open capillary tubes on a Büchi B-540 apparatus and are uncorrected. High resolution mass spectra (HRMS) were recorded using a Micromass LCT Premier XE instrument (Waters) and were determined by electrospray ionization (ESI) with a TOF analyzer.

2. Synthesis and Characterization of the gold(I) complexes (S)-5, (S)-6, (S)-7

and (S)-11a

Synthesis of (S)-2,2'-bis(methoxymethoxy)-1,1'-binaphthalene



(S)-BINOL (14.3 g, 50.0 mmol, 1.0 equiv.) was dissolved in 80 mL of anhydrous THF and added dropwise to a suspension of NaH (60 % wt in mineral oil, 6.0 g, 150 mmol, 3 equiv.) in 80 ml of anhydrous THF at 0 °C. The reaction mixture was stirred for 1 h at room temperature and then MOM-Cl (11.4 mL, 150 mmol, 3 equiv.) was added dropwise at 0 °C. The reaction mixture was stirred for another 3 hours at room temperature. When the reaction was completed, it was quenched with saturated aqueous NaHCO₃ and extracted twice with CH_2Cl_2 . Combined organic layers were then dried over MgSO₄ and evaporated. The crude product was used directly for further synthesis without purification (18.5 g, 49.4 mmol, 99 %).

IR (neat) v_{max} = 3057, 2956, 2901, 2826, 1621, 1592, 1506, 1237, 1147, 1031, 1011, 920, 809, 749 cm⁻¹. ¹H NMR (CDCl₃, 300 MHz) δ (ppm) = 7.92 (d, *J* = 9.0 Hz, 2H), 7.84 (d, *J* = 8.3 Hz, 2H), 7.55 (d, *J* = 9.0 Hz, 2H), 7.33-7.28 (m, 2H), 7.22-7.14 (m, 4H), 5.05 (d, *J* = 6.8 Hz, 2H), 4.94 (d, *J* = 6.8 Hz, 2H), 3.11 (s, 6H). ¹³C NMR (CDCl₃, 75 MHz) δ (ppm) = 152.8, 134.2, 130.0, 129.5, 128.0, 126.5, 125.7, 124.2, 121.4, 117.4, 95.3, 56.0.

Synthesis of (*S*)-2- (2,2'-*bis*(methoxymethoxy)- [1,1'-binaphthalen]-3-yl)- 4,4,5,5-tetramethyl-1,3,2-dioxaborolane [(*S*)-1]



To a solution of (*S*)-2,2'-bis(methoxymethoxy)-1,1'-binaphthalene (7.84 g, 21 mmol, 1.0 equiv.) in 140 mL of anhydrous THF, *n*-BuLi (19.6 mL, 29.4 mmol, 1.4 equiv.) was added dropwise at -78 °C. The reaction mixture was stirred at -78 °C for 4 hours, then isopropoxypinacolborate (5.6 mL, 27.3 mmol, 1.3 equiv.) was added to the flask and the resulting solution was allowed to warm to room temperature. It was stirred overnight at room temperature and then quenched with water and extracted with DCM. Combined organic layers were dried over MgSO₄ and evaporated. The crude product was purified by flash column chromatography on silica gel (pure heptane to heptane:DCM = 2:1) yielding the product as a white solid (7.03 g, 14.1 mmol, 67 %).¹

IR (neat) v_{max} = 3411, 3054, 2956, 2825, 1909, 1622, 1592, 1436, 1241, 1146, 1014, 988, 923, 696 cm⁻¹. ¹H NMR (CDCl₃, 300 MHz) δ = 8.49 (s, 1H), 7.92 (d, *J* = 8.9 Hz, 2H), 7.82 (d, *J* = 8.1 Hz, 1H), 7.55 (d, *J* = 9.0 Hz, 1H), 7.39-7.29 (m, 2H), 7.27-7.17 (m, 4H), 5.15 (d, *J* = 6.8 Hz, 1H), 4.93 (d, *J* = 7.0 Hz, 1H), 4.89 (d, *J* = 5.8 Hz, 1H), 4.84 (d, *J* = 5.8 Hz, 1H), 3.11 (s, 3H), 2.40 (s, 3H), 1.39 (s, 12H). ¹³C NMR (CDCl₃, 75 MHz) δ (ppm) = 156.9, 153.1, 139.4, 135.9, 134.5, 130.5, 129.8, 129.5, 128.7, 127.7, 127.5, 126.5, 126.3, 126.1, 125.5, 124.8, 124.1, 121.8, 116.9, 100.2, 100.1, 95.2, 84.0, 56.0, 55.9, 25.0. HRMS (ESI): *m/z*: calcd for C₃₀H₃₃BNaO₆⁺ 523.2262 [M+*Na*]⁺, found, 523.2313. [*a*]_D = -68 (*c* 1.16, CHCl₃).

Synthesis of (2-bromophenyl)diphenylphosphine oxide²



Diphenylphosphine oxide (4.81 g, 23.8 mmol, 1.0 equiv.) was dissolved in PhMe (60 mL), and then $Pd_2(dba)_3$ (0.38 g, 0.4 mmol, 1.75 mol %), 1,3-bis(diphenylphosphino)propane (0.34 g, 0.8 mmol, 3.5 mol %), then bromoiodobenzene (3.36 mL, 26.2 mmol, 1.1 equiv.), and ^{*i*}Pr₂NEt (4.9 mL, 29.7 mmol, 1.25

¹ L.-X. Gao; Ma, L.; Jin, R.-Z.; Lü, G.-H.; Bian, Z.; Ding, M.-X. Synthesis **2007**, 2461-2470.

² H.-L. Wang; Hu, R.-B.; Zhang, H.; Zhou, A.-X.; Yang, S.-D. Org. Lett. **2013**, *15*, 5302-5305.

equiv.) were added and the mixture stirred at 90 °C for 4 days. After cooling to room temperature, water was added and the solution was extracted with DCM. Organic layers were dried over MgSO₄, filtered and evaporated under vacuum. The crude product was purified by flash column chromatography (Hept: EA = 4:1 to EA), giving product as a pale yellow solid (6.0 g, 16.8 mmol, 64 %).

¹H NMR (CDCl₃, 500 MHz) δ = 7.75-7.65 (m, 5H), 7.58-7.53 (m, 2H), 7.60-7.45 (m, 4H), 7.41-7.30 (m, 3H). ¹³C NMR (CDCl₃, 75 MHz) δ = 136.1 (d, J_{c-p} = 10.4 Hz), 135.0 (d, J_{c-p} = 7.7 Hz), 133.6 (d, J_{c-p} = 2.2 Hz), 133.2 (d, J_{c-p} = 104.3 Hz), 132.3 (d, J_{c-p} = 9.9 Hz), 132.1 (d, J_{c-p} = 2.7 Hz), 131.9 (d, J_{c-p} = 107.6 Hz), 128.7 (d, J_{c-p} = 12.6 Hz), 127.1 (d, J_{c-p} = 11.5 Hz), 127.1 (d, J_{c-p} = 4.9 Hz). ³¹P NMR (CDCl₃, 200 MHz) δ = 30.6.

Synthesis of (S)-(2-(2,2'-dihydroxy-[1,1'-binaphthalen]-3-yl)phenyl) diphenylphosphine oxide [(S)-2] ³



(2-bromophenyl)diphenylphosphine oxide (4.44 g, 12.5 mmol, 1.5 equiv.) and Pd(PPh₃)₄ (0.48 g, 0.42 mmol, 5 mol %) were added to a flask, followed by anhydrous, degassed THF (100 mL) and H₂O (50 mL). The mixture was stirred at room temperature for 10 min. To this solution were added (*S*)-2-(2,2'-bis(methoxymethoxy)-[1,1'-binaphthalen]-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (4.78 g, 8.3 mol, 1.0 equiv.) [(*S*)-1] and K₂CO₃ (3.45 g, 24.9 mmol, 3 equiv.), and the solution was stirred at 100 °C for 24 h. After cooling to room temperature, water was added and the reaction mixture was extracted twice with methyl *tert*-butyl ether. The combined organic layers were dried over MgSO₄, filtered and concentrated under vacuum.

The crude product was dissolved in a mixture of THF/MeOH 1:1 (80 mL), then p-TsOH·H₂O was added to this solution and reaction mixture was stirred at 60 °C for 3 hours. After that, it was cooled down to room temperature and solvents were evaporated under reduced pressure. Water was added and the reaction mixture was extracted twice with DCM. The combined organic layers were dried over MgSO₄, filtered and concentrated under vacuum. The crude product was purified by flash column chromatography (eluent: 100 % heptane to heptane/ethyl acetate, 30/70) giving the product as a white solid (3.43 g, 6.1 mmol, 74 %).

IR (neat) $v_{max} = 3058$, 1619, 1467, 1438, 1142, 750 cm⁻¹. ¹H NMR (CDCl₃, 500 MHz) $\delta = 8.11$ (br s, 1H), 7.83 (d, J = 8.8 Hz, 1H), 7.77 (d, J = 8.2 Hz, 1H), 7.67 (dd, $J_1 = 11.6$ Hz, $J_2 = 7.6$ Hz, 2H), 7.61 (t, J = 7.6 Hz, 1H), 7.58-7.54 (m, 1H), 7.46 (t, J = 6.9 Hz, 1H), 7.42-7.30 (m, 4H), 7.29-7.06 (m, 12H), 6.97 (s, 1H), 6.93 (d, J = 7.9 Hz, 1H), 5.74 (s, 1H). ¹³C NMR (CDCl₃, 125 MHz) $\delta = 154.0$, 151.4, 143.6 (d, $J_{c-p} = 7.3$ Hz), 134.5, 133.9, 133.5 (d, $J_{c-p} = 13.7$ Hz), 133.0, 132.6 (d, $J_{c-p} = 1.8$ Hz), 132.5 (d, $J_{c-p} = 9.2$ Hz), 132.4 (d, $J_{c-p} = 158.5$ Hz), 132.2 (d, $J_{c-p} = 2.7$ Hz), 132.0 (d, $J_{c-p} = 10.1$ Hz), 131.9, 131.9, 131.4, 131.3, 131.3, 131.2 (d, $J_{c-p} = 106.3$ Hz), 130.5, 130.1, 129.0 (d, $J_{c-p} = 50.4$ Hz), 128.7 (d, $J_{c-p} = 11.9$ Hz), 128.4 (d, $J_{c-p} = 12.8$ Hz), 128.3 (d, $J_{c-p} = 6.4$ Hz), 127.4 (d, $J_{c-p} = 12.8$ Hz), 126.7, 126.8, 125.4, 123.7, 123.3, 120.2, 115.4, 113.1. ³¹P NMR (CDCl₃,

³ H. Sasai; Matsui, K.; Takizawa, S. Synlett **2006**, *5*, 761-765.

200 MHz) δ = 30.5. **HRMS (ESI)**: *m*/*z*: calcd for C₃₈H₂₈O₃P⁺ 563.1771 [M+H]⁺, found, 563.1770. [α]_D = +71 (*c* 0.76, CHCl₃), *lit* +86 (*c* 0.6, CHCl₃).

2.Synthesis of (S)-3-(2-(diphenylphosphaneyl)phenyl)-[1,1'-binaphthalene]-2,2'-diol [(S)-3]³



(*S*)-(2-(2,2'-dihydroxy-[1,1'-binaphthalen]-3-yl)phenyl)diphenylphosphine oxide [(*S*)-2] (3.43 g, 6.1 mmol, 1.0 equiv.) was dissolved in toluene (100 mL) at 0 °C, and then Et₃N (8.5 mL, 61 mmol, 10 equiv.) and Cl₃SiH (12.5 mL, 122.1 mmol, 20 equiv.) were added to the solution dropwise at 0 °C. The reaction was then stirred at 90 °C for 24 h. After cooling to room temperature, the reaction solution was quenched with 2 M NaOH and then THF was evaporated under reduced pressure. 2 M NaOH was added to dissolve the precipitated solid and then extracted twice with DCM, dried over MgSO₄ and evaporated. The crude product was purified by flash column chromatography (eluent: heptane to DCM) giving the product as a white solid (2.61 g, 4.7 mmol, 78 %).

IR (neat) $v_{max} = 3510$, 3053, 1619, 1596, 1434, 1138, 734 cm⁻¹. ¹H NMR (CDCl₃, 500 MHz) $\delta = 7.94$ (d, J = 8.8 Hz, 1H), 7.87 (d, J = 7.9 Hz, 1H), 7.64-7.57 (m, 1H), 7.55-7.42 (m, 3H), 7.40-7.15 (m, 17H), 7.11-7.03 (m, 2H), 5.71 (bs, 1H), 5.15 (bs, 1H). ¹³C NMR (CDCl₃, 125 MHz) $\delta = 153.2$, 150.1, 143.2 (d, $J_{c-p} = 30.2$ Hz), 138.2 (d, $J_{c-p} = 30.2$ Hz), 136.9 (d, $J_{c-p} = 8.2$ Hz), 136.7 (d, $J_{c-p} = 9.2$ Hz), 134.1, 134.0, 133.8 (d, $J_{c-p} = 19.2$ Hz), 132.3, 131.2, 130.5, 130.3 (d, $J_{c-p} = 3.7$ Hz), 129.6, 129.5, 128.8, 128.6, 128.5, 128.5, 128.5, 127.6, 127.5, 127.2, 125.1, 124.9, 124.2, 123.9, 118.1 (d, $J_{c-p} = 82.5$ Hz), 112.1, 112.0. ³¹P NMR (CDCl₃, 120 MHz) $\delta = -10.6$, -12.3. HRMS (ESI): m/z: calcd for $C_{38}H_{28}O_2P^+$ 547.1821 [M+H]⁺, found, 547.1801. [α]_D = -80 (*c* 0.94, CHCl₃), *lit* -73 (*c* 0.6, CHCl₃).

Synthesis of (*S*)-(2-(2,2'-dihydroxy-[1,1'-binaphthalen]-3-yl)phenyl)diphenylphosphine gold(I) chloride [(*S*)-4]



(S)-3-(2-(diphenylphosphaneyl)phenyl)-[1,1'-binaphthalene]-2,2'-diol [**(S)**-3] (2.63 g, 4.8 mmol, 1.0 equiv.) and Me₂S•AuCl (1.41 g, 4.8 mmol, 1.0 equiv.) were dissolved in dry DCM (130 mL), and then the reaction solution was stirred at room temperature for 1 h. The solvent was evaporated and the crude product was purified by flash column chromatography (Heptane-DCM), yielding the product as a white

solid (3.4 g, 4.4 mmol, 89 %).

IR (neat) v_{max} = 3515, 3405, 3057, 2926, 1619, 1597, 1437, 1131, 748 cm⁻¹. ¹H NMR (CDCl₃, 500 MHz) δ = 7.87 (d, *J* = 8.8 Hz, 1H), 7.79 (d, *J* = 7.9 Hz, 1H), 7.63-7.61 (m, 1H), 7.58-7.49 (m, 4H), 7.50-7.47 (m, 1H), 7.46-7.40 (m, 4H), 7.39-7.34 (m, 3H), 7.34-7.23 (m, 5H), 7.23-7.16 (m, 4H), 7.00 (d, *J* = 8.2 Hz, 1H), 6.53 (br s, 1H), 4.90 (br s, 1H). ¹³C NMR(CDCl₃, 125 MHz) δ = 154.3, 150.2, 144.0 (d, *J*_{c-p} = 15.6 Hz), 134.8 (d, *J*_{c-p} = 5.5 Hz), 134.5 (d, *J*_{c-p} = 13.7 Hz), 134.3 (d, *J*_{c-p} = 13.7 Hz), 134.2, 133.7 (d, *J*_{c-p} = 8.2 Hz), 133.5, 133.1, 132.1 (d, *J*_{c-p} = 1.8 Hz), 131.7 (d, *J*_{c-p} = 1.8 Hz), 131.6, 131.5 (d, *J*_{c-p} = 1.8 Hz), 130.9 (d, *J*_{c-p} = 62.3 Hz), 129.9, 129.6 (d, *J*_{c-p} = 12.8 Hz), 129.4, 129.2 (d, *J*_{c-p} = 11.9 Hz), 129.0, 128.7, 128.6, 128.6, 128.2, 128.1, 127.8, 127.4, 124.9, 124.8, 124.1, 123.8, 119.4, 113.6, 110.4. ³¹P NMR (CDCl₃, 200 MHz) δ = 24.2. HRMS (ESI): *m/z*: calculated for C₄₀H₃₀AuNO₂P⁺: 784.1680 [M+MeCN-Cl]⁺, found, 784.1688; *m/z*: calcd for C₃₈H₂₆AuClO₂P⁻ 777.1030 [M-H]⁻, found, 777.1016. [α]_p = -149 (*c* 1.07, CHCl₃).

Synthesis of (*S*)-(2-(2,2'-diyl hydrogen phosphate-[1,1'-binaphthalen]-3-yl)phenyl) diphenylphosphine gold(I) chloride [(*S*)-5]



(*S*)-(2-(2,2'-dihydroxy-[1,1'-binaphthalen]-3-yl)phenyl)diphenylphosphine gold(I) chloride [(*S*)-4] (3.4 g, 4.3 mmol, 1.0 equiv.) was added to 10 mL pyridine, then POCl₃ (0.48 mL, 5.11 mmol, 1.2 equiv.) was added to the solution dropwise under 0 °C. The resulting solution was stirred at room temperature for 24 h. After completion, it was quenched with water and the solvent were removed under vacuum. 2M HCl and THF were added, and the reaction mixture was stirred overnight at 50 °C. After cooling to room temperature, the reaction solution was extracted with DCM and H₂O. Crude product was purified by flash column chromatography (eluent: heptane to DCM) giving the product as a brown solid (3.15 g, 3.7 mmol, 88 %).

m.p.: 256.2-261.5 °C. **IR (neat)** v_{max} = 3515, 3405, 3056, 2925, 1619, 1436, 1214, 1131, 748 cm⁻¹. **HRMS (ESI)**: m/z calcd for C₄₀H₂₉AuNO₄P₂⁺ 846.1232 [M+MeCN-Cl⁻]⁺, found, 846.1245; m/z calcd for C₃₈H₂₅AuClO₄P₂⁻ 839.0588 [M-H]⁻, found, 839.0587. [α]_D = +15 (*c* 1.03, CHCl₃).

-NMR data in DMSO-d6:

¹H NMR (DMSO-d6, 343K, 500 MHz) δ = 8.13-8.07 (m, 2H), 8.06 (d, *J* = 6.6 Hz, 1H), 8.03 (d, *J* = 8.2 Hz, 1H), 7.86 (d, *J* = 8.2 Hz, 1H), 7.72 (t, *J* = 7.6 Hz, 2H), 7.62 (d, *J* = 6.3 Hz, 1H), 7.60-7.48 (m, 7H), 7.43 (d, *J* = 8.8 Hz, 1H), 7.40 (d, *J* = 9.1 Hz, 1H), 7.37-7.28 (m, 4H), 7.18-7.10 (m, 2H), 7.00 (br s, 2H), 6.24 (br s, 1H).

¹³C NMR (DMSO-d6, 343K, 125 MHz) δ = 146.9 (d, J_{c-p} = 9.2 Hz), 144.9 (d, J_{c-p} = 10.1 Hz), 141.5 (d, J_{c-p} = 13.7 Hz), 133.8 (d, J_{c-p} = 7.3 Hz), 133.6 (d, J_{c-p} = 13.7 Hz), 133.3 (d, J_{c-p} = 13.7 Hz), 132.9 (d, J_{c-p} = 6.4 Hz), 131.8, 131.5, 131.3 (d, J_{c-p} = 5.5 Hz), 131.2, 131.0 (d, J_{c-p} = 116.4 Hz), 130.7, 130.3, 129.8, 129.5, 129.4, 129.1 (d, J_{c-p} = 11.0 Hz), 128.4, 128.4 (d, J_{c-p} = 12.8 Hz), 128.0 (d, J_{c-p} = 9.2 Hz), 127.6, 127.6, 127.4 (d, J_{c-p} = 12.8 Hz), 126.9 (d, J_{c-p} = 15.6 Hz), 126.4, 125.9, 125.6, 125.2, 124.9, 121.7, 121.0, 120.7, 120.3.

³¹P NMR (DMSO-d6, 343 K, 200 MHz) δ = 26.4, 1.2 (major isomer) and 25.8, 2.5 (minor isomer). ³¹P NMR (DMSO-d6, 383 K, 200 MHz) δ = 26.8, 1.1.

-NMR data in deuterated pyridine:



¹H NMR (Pyridine-d5, 500 MHz) δ = 11.86 (bs, 1H), 9.26 (t, J = 6.3 Hz, 1H), 7.97 (s, 1H), 7.88 (d, J = 8.0 Hz, 1H), 7.84 (t, J = 7.7 Hz, 1H), 7.82-7.75 (m, 3H), 7.72 (d, J = 8.7 Hz, 1H), 7.63 (dd, J_1 = 13.2 Hz, J_2 = 7.7 Hz, 2H), 7.53 (t, J = 6.9 Hz, 1H), 7.49-7.33 (m, 9H), 7.20 (t, J = 7.6 Hz, 1H), 7.15 (dd, J_1 = 12.1 Hz, J_2 = 7.9 Hz, 1H), 6.99 (t, J = 6.8 Hz, 2H), 6.92 (t, J = 6.9 Hz, 1H).

¹³C NMR (Pyridine-d5, 125 MHz) δ = 148.6 (d, *J_{c-p}* = 10.1 Hz), 144.1 (d, *J_{c-p}* = 13.7 Hz), 136.9 (d, *J_{c-p}* = 7.3 Hz), 135.6 (d, *J_{c-p}* = 14.7 Hz), 134.7, 134.7 (d, *J_{c-p}* = 13.7 Hz), 134.1, 133.9, 133.7 (d, *J_{c-p}* = 4.6 Hz), 133.5, 132.8, 132.4, 132.1, 131.7, 131.6 (d, *J_{c-p}* = 62.3 Hz), 131.3, 130.7, 130.3 (d, *J_{c-p}* = 11.9 Hz), 130.3, 129.9, 129.8, 129.7 (d, *J_{c-p}* = 11.0 Hz), 129.4, 129.0 (d, *J_{c-p}* = 10.1 Hz), 128.8, 128.7, 128.3, 127.8, 127.6, 127.3, 126.2, 126.0, 123.1.

³¹P NMR (Pyridine-d5, 200 MHz) δ = 29.2, 6.7.

-NMR data in CDCl₃:

¹H NMR (CDCl₃, 500 MHz) δ = 8.30 (s, 1H), 8.04 (d, J = 8.2 Hz, 1H), 7.90 (d, J = 8.2 Hz, 2H), 7.77-7.72 (m, 1H), 7.58-7.48 (m, 5H), 7.46-7.39 (m, 3H), 7.35-7.19 (m, 8H), 6.97 (dd, J_1 = 11.9 Hz, J_2 = 7.9 Hz, 1H), 6.73-6.66 (m, 2H), 6.66-6.60 (m, 1H), 6.53 (bs, 1H).

³¹P NMR (CDCl₃, 200 MHz) δ = 27.7, 2.9 (major isomer), 26.2, 4.6 (minor isomer).

Isolation of the intermediate phosphoroyl chloride SI-1

In some reaction batch for the synthesis of **5**, one of the intermediate phosphoroyl chloride diastereoisomer was showed to be poorly reactive towards hydrolysis and could be isolated and characterized.



Data for (S)-(2-(2,2'-diylchlorogenphosphate-[1,1'-binaphthalen]-3-yl)phenyl) diphenylphosphine gold(I) chloride [SI-1]: m.p.: 193.4-194.2 °C. IR (neat) v_{max} =

3056, 2961, 2925, 2854, 1591, 1437, 1413, 1310, 1242, 1208, 1101, 1082, 970, 954, 904, 821, 876, 750, 693. ¹H NMR (CDCl₃, 500 MHz) δ = 8.37 (s, 1H), 8.09 (d, *J* = 8.2 Hz, 1H), 8.03 (d, *J* = 8.8 Hz, 1H), 7.97 (d, *J* = 8.2 Hz, 1H), 7.85 (t, *J* = 6.3 Hz, 1H), 7.71 (t, *J* = 7.6 Hz, 1H), 7.62-7.55 (m, 2H), 7.52-7.45 (m, 5H), 7.45-7.40 (m, 3H), 7.40-7.31 (m, 4H), 7.25 (d, *J* = 9.1 Hz, 1H), 7.07 (dd, *J*₁ = 12.0 Hz, *J*₂ = 8.2 Hz, 1H), 6.74-6.69 (m, 3H). ¹³C NMR (CDCl₃, 125 MHz) δ = 146.1 (d, *J*_{c-p} = 11.9 Hz), 143.9 (d, *J*_{c-p} = 11.9 Hz), 141.1 (d, *J*_{c-p} = 12.8 Hz), 134.9 (d, *J*_{c-p} = 14.7 Hz), 134.6 (d, *J*_{c-p} = 14.7 Hz), 134.1 (d, *J*_{c-p} = 7.3 Hz), 133.8, 133.2 (d, *J*_{c-p} = 6.4 Hz), 132.6, 132.2, 131.9, 131.9, 131.7, 131.7, 131.5, 130.9 (d, *J*_{c-p} = 1.8 Hz), 129.8, 129.6, 129.4 (d, *J*_{c-p} = 11.9 Hz), 129.0, 128.9 (d, *J*_{c-p} = 8.2 Hz), 128.9, 128.8, 128.6, 128.4, 128.0, 127.5, 127.0 (d, *J*_{c-p} = 68.7 Hz), 126.8, 122.1, 121.8, 121.8, 119.6 (d, *J*_{c-p} = 2.7 Hz). ³¹P NMR (CDCl₃, 200 MHz) δ = 26.8, 9.2. HRMS (ESI): *m/z* calcd for C₄₀H₂₈AuClNO₃P₂⁺ 864.0893 [M+MeCN-Cl⁻]⁺, found, 864.0898.

This compound **SI-1** could be submitted to hydrolysis according to the following procedure.



To a solution of **SI-1** (436 mg, 0.51 mmol) in THF (30 mL) was added 2 M HCl (30 mL). The resulting mixture was then stirred overnight at 50 °C. After cooling to room temperature, the THF was removed under vacuum and the resulting solution was extracted with DCM. Organic layers were dried over MgSO₄, filtered and evaporated under vacuum. The crude product was purified by flash column chromatography, giving product **(S)-5** as a brown solid (350.0 mg, 0.42 mmol, 82 %).

Synthesis of (S)-6



To a suspension of Ag_2CO_3 (82.8 mg, 0.3 mmol) in toluene (2 mL) and H_2O (2 mL), **(S)-5** (84.1 mg, 0.1 mmol) was added. The mixture was stirred overnight at room temperature. Then the suspension was filtered on celite. The filter was rinsed with DCM and evaporated under vacuum. The product was obtained as an amorphous gray solid (56.1 mg, 0.07 mmol, 69 %). This Au(I) complex is also very cleanly generated by performing the reaction in pure CDCl₃ within 1 h.

IR (neat) ν_{max} = 3656, 3410, 3054, 2923, 2852, 1621, 1592, 1509, 1480, 1436, 1417, 1330, 1263, 1227, 1101, 1080, 1052, 997, 967, 950, 869, 850, 816, 749, 712, 694.

HRMS (ESI): m/z calcd for C₄₀H₂₉AuNO₄P₂⁺ 846.1232 [M+H+MeCN]⁺, found, 846.1232; HRMS (ESI): m/z calcd for C₃₉H₂₆AuO₆P₂⁻ 849.0876 [M+HCOO]⁻, found, 849.0867. [α]_D = +39 (*c* 1.12, CHCl₃).

-NMR data in Pyridine-d5

¹H NMR (Pyridine, 500 MHz) δ = 8.12-7.98 (m, 3H), 7.92 (d, *J*= 8.9 Hz, 1H), 7.89 (d, *J*= 8.2 Hz, 1H), 7.82-7.74 (m, 3H), 7.70 (td, *J*₁ = 7.6 Hz, *J*₂ = 1.8 Hz, 2H), 7.57 (d, *J*= 9.2 Hz, 1H), 7.50-7.44 (m, 3H), 7.44-7.32 (m, 7H), 7.30-7.27 (m, 1H), 7.20-7.08 (m, 4H).

¹³C NMR (Pyridine, 125 MHz) δ = 152.0 (d, *J*_{*c*-*p*} = 9.2 Hz), 149.4 (d, *J*_{*c*-*p*} = 8.2 Hz), 144.8 (d, *J*_{*c*-*p*} = 14.7 Hz), 136.4, 135.8 (d, *J*_{*c*-*p*} = 13.7 Hz), 135.6, 135.4 (d, *J*_{*c*-*p*} = 5.5 Hz), 134.7 (d, *J*_{*c*-*p*} = 12.8 Hz), 134.2 (d, *J*_{*c*-*p*} = 8.2 Hz), 133.8, 133.2, 133.1, 133.1 (d, *J*_{*c*-*p*} = 128.3 Hz), 132.1, 131.8 (d, *J*_{*c*-*p*} = 45.8 Hz), 130.9, 130.5 (d, *J*_{*c*-*p*} = 11.9 Hz), 130.4 (d, *J*_{*c*-*p*} = 79.7 Hz), 129.9, 129.9, 129.6, 129.3, 129.0, 128.7 (d, *J*_{*c*-*p*} = 9.2 Hz), 127.9, 127.4, 127.1,

126.7, 125.9, 125.0, 124.9 (d, J_{c-p} = 127.4 Hz), 123.8, 123.5, 122.8. ³¹P NMR (Pyridine, 200 MHz) δ = 22.9, 8.6.

-NMR data in CDCl₃

¹H NMR (CDCl₃, 500 MHz) δ = 7.80 (d, *J* = 8.2 Hz, 1H), 7.76 (d, *J* = 8.9 Hz, 1H), 7.65 (brs, 2H), 7.52-7.23 (m, 16H), 7.20-7.10 (m, 2H), 7.00-6.85 (m, 3H).

³¹P NMR (CDCl₃, 200 MHz) δ = 21.8, 8.3.

Synthesis of (S)-(2-(2,2'-diyl hydrogen phosphate-[1,1'-binaphthalen]-3-yl)phenyl)
 diphenylphosphine gold(I) bis(trifluoromethanesulfonyl)imide (S)-7a



To a suspension of $AgNTf_2$ (16.8 mg, 0.030 mmol) in toluene (1 mL), **(S)-6** (16.8 mg, 0.020 mmol) was added. The mixture was stirred overnight at room temperature. Then the suspension was filtered on celite. The filter was rinsed with DCM and evaporated under vacuum. The product was obtained as an amorphous gray solid (17.8 mg, 0.016 mmol, 82 %).

IR (neat) v_{max} = 3061, 1592, 1438, 1401, 1353, 1209, 1198, 1131, 1082, 1060, 1028, 958, 900, 830, 751. [α]_D = +170 (*c* 1.16, CHCl₃). HRMS (ESI): *m/z* calcd for C₄₀H₂₉AuNO₄P₂⁺ 846.1232 [M-NTf₂+H+MeCN]⁺, found, 846.1224.

-NMR data in CDCl₃

¹H NMR (CDCl₃, 500 MHz) δ = 8.32 (s, 1H), 8.17 (d, *J* = 8.2 Hz, 1H), 7.95 (d, *J* = 8.2 Hz, 1H), 7.92 (d, *J* = 8.8 Hz, 1H), 7.65-7.59 (m, 2H), 7.59-7.52 (m, 3H), 7.52-7.37 (m, 6H), 7.37-7.28 (m, 3H), 7.27-7.18 (m, 3H), 6.96 (dd, *J*₁ = 12.3 Hz, *J*₂ = 7.9 Hz, 1H), 6.60-6.52 (m, 1H), 6.50-6.38 (m, 2H), 5.69 (bs, 1H).

¹³C NMR (CDCl₃, 125 MHz) δ = 146.2 (d, J_{c-p} = 5.5 Hz), 143.7 (d, J_{c-p} = 4.6 Hz), 142.0 (d, J_{c-p} = 12.8 Hz), 135.3 (d, J_{c-p} = 14.7 Hz), 134.4 (d, J_{c-p} = 13.7 Hz), 133.3 (d, J_{c-p} = 7.3 Hz), 133.1 (d, J_{c-p} = 8.2 Hz), 132.6 (d, J_{c-p} = 108.1 Hz), 132.5 (d, J_{c-p} = 1.8 Hz), 132.5, 131.6, 131.5 (d, J_{c-p} = 46.7 Hz), 131.5 (d, J_{c-p} = 1.8 Hz), 131.4, 130.7 (d, J_{c-p} = 6.4 Hz), 129.8 (d, J_{c-p} = 12.8 Hz), 129.3, 129.0, 128.9, 128.9, 128.6, 128.0, 127.8 (d, J_{c-p} = 20.2 Hz), 127.0, 126.7, 126.4, 124.4 (d, J_{c-p} = 67.8 Hz), 123.4, 121.6 (d, J_{c-p} = 103.6 Hz), 120.8, 119.5, 118.3.

³¹P NMR (CDCl₃, 200 MHz) δ = 22.9, 2.9.

-NMR data in deuterated pyridine

¹H NMR (Pyridine-d5, 500 MHz) δ = 11.45 (br s, 1H), 8.05-7.97 (m, 3H), 7.93-7.80 (m, 3H), 7.75 (td, J_1

= 7.6 Hz, J₂ = 1.8 Hz, 1H), 7.69-7.28 (m, 15H), 7.25 (d, J = 7.5 Hz, 1H), 7.19 (d, J = 7.6 Hz, 1H), 7.11 (d, J = 8.5 Hz, 1H).

³¹P NMR (Pyridine-d5, 200 MHz) δ = 22.8, 7.6 (major isomer), 27.9, 7.1 (minor isomer).

Synthesis of SI-2



(*S*)-(2-(2,2'-diylchlorogenphosphate-[1,1'-binaphthalen]-3-yl)phenyl) diphenylphosphine gold(I) chloride **[SI-1]** (122 mg, 0.14 mmol, 1.0 equiv.) was added to methanol (5 mL), the result solution was then stirred overnight at 35 °C. The methanol was removed and the crude product was purified by flash column chromatography, giving product as a white solid (69.0 mg, 0.08 mmol, 57 %).

IR (neat) v_{max} = 3056, 2958, 2923, 2856, 1620, 1592, 1437, 1300, 1218, 1187, 1101, 1051, 993, 974, 955, 892, 829, 750, 694. ¹H NMR (CDCl₃, 500 MHz) δ = 8.27 (s, 1H), 8.01-7.95 (m, 3H), 7.93 (d, *J* = 8.2 Hz, 1H), 7.71 (t, *J* = 7.6 Hz, 1H), 7.56-7.47 (m, 5H), 7.47-7.39 (m, 4H), 7.39-7.31 (m, 4H), 7.30-7.24 (m, 1H), 7.20 (d, *J* = 8.5 Hz, 1H), 7.05 (dd, *J*₁ = 11.6 Hz, *J*₂ = 7.9 Hz, 1H), 6.82-6.72 (m, 3H), 3.66 (d, *J* = 11.7 Hz, 3H). ¹³C NMR (CDCl₃, 125 MHz) δ = 147.0 (d, *J*_{c-p} = 11.0 Hz), 143.6 (d, *J*_{c-p} = 8.2 Hz), 141.6 (d, *J*_{c-p} = 12.8 Hz), 134.8 (d, *J*_{c-p} = 8.2 Hz), 134.6 (d, *J*_{c-p} = 9.2 Hz), 134.4 (d, *J*_{c-p} = 8.2 Hz), 133.4, 133.2 (d, *J*_{c-p} = 7.3 Hz), 132.5 (d, *J*_{c-p} = 43.1 Hz), 131.9 (d, *J*_{c-p} = 1.8 Hz), 131.7 (d, *J*_{c-p} = 1.8 Hz), 131.6 (d, *J*_{c-p} = 2.7 Hz), 131.3, 131.1, 131.1, 131.0, 130.5 (d, *J*_{c-p} = 143.0 Hz), 129.5, 129.4, 129.3, 128.8, 128.7, 128.6, 128.6, 128.2, 127.8 (d, *J*_{c-p} = 135.6 Hz), 127.7, 127.6, 127.2, 126.8, 126.4 (d, *J*_{c-p} = 64.2 Hz), 122.2, 121.3, 119.7 (d, *J*_{c-p} = 2.7 Hz), 55.8 (d, *J*_{c-p} = 5.5 Hz). ³¹P NMR (CDCl₃, 200 MHz) δ = 27. 2, 1.2. HRMS (ESI): *m/z* calcd for C₄₁H₃₁AuNO₄P₂⁺ 860.1388 [M+MeCN-Cl⁻]⁺, found, 860.1390; *m/z* calcd for C₃₈H₂₅AuClO₄P₂⁻ 839.0588 [M-CH₃⁻, found, 839.0576.

Synthesis of (S)-11a



SI-2 (16.7mg, 0.02 mmol, 1.0 equiv.) and $AgNTf_2$ (7.5 mg, 0.02 mmol, 1.0 equiv.) were added to 1 mL CDCl₃, the resulting solution was then stirred at room temperature for 2 h. The reaction solution was filtered and evaporated, giving product **11** as a white solid (18.8 mg, 0.02 mmol, 79 %).

IR (neat) v_{max} = 3059, 2961, 2927, 2856, 1537, 1438, 1400, 1354, 1300, 1261, 1210, 1193, 1131, 1102,

1055, 975, 957, 895, 830, 751, 693. ¹H NMR (CDCl₃, 500 MHz) δ = 8.35 (s, 1H), 8.15 (d, J = 8.2 Hz, 1H), 7.96 (d, J = 8.8 Hz, 1H), 7.95 (d, J = 7.6 Hz, 1H), 7.85 (t, J = 6.3 Hz, 1H), 7.74 (t, J = 7.6 Hz, 1H), 7.59 (t, J = 7.6 Hz, 1H), 7.55 (t, J = 7.6 Hz, 1H), 7.55 (s, 1H), 7.51-7.42 (m, 5H), 7.38 (t, J = 7.6 Hz, 1H), 7.36 (t, J = 7.6 Hz, 1H), 7.29 (d, J = 8.8 Hz, 2H), 7.27-7.21 (m, 3H), 6.98 (dd, J_1 = 12.6 Hz, J_2 = 7.9 Hz, 1H), 6.58 (t, J = 6.9 Hz, 1H), 6.48 (t, J = 6.6 Hz, 2H), 3.71 (d, J = 11.7 Hz, 3H). ¹³C NMR (CDCl₃, 125 MHz) δ = 146.9 (d, J_{c-p} = 11.0 Hz), 143.2 (d, J_{c-p} = 8.2 Hz), 141.9 (d, J_{c-p} = 12.8 Hz), 135.2 (d, J_{c-p} = 15.6 Hz), 134.4 (d, J_{c-p} = 13.7 Hz), 134.2 (d, J_{c-p} = 7.3 Hz), 132.9 (d, J_{c-p} = 9.2 Hz), 132.8, 132.6 (d, J_{c-p} = 106.3 Hz), 132.4 (d, J_{c-p} = 2.7 Hz), 131.9 (d, J_{c-p} = 2.7 Hz), 131.8 (d, J_{c-p} = 1.8 Hz), 131.6, 131.3, 131.3, 130.6 (q, J_{c-p} = 2.7 Hz), 129.7 (d, J_{c-p} = 11.9 Hz), 129.1, 128.9 (d, J_{c-p} = 10.1 Hz), 128.8 (d, J_{c-p} = 67.8 Hz), 122.2, 121.0, 120.8, 119.6 (d, J_{c-p} = 2.7 Hz), 118.3, 55.5 (d, J_{c-p} = 4.6 Hz). ³¹P NMR (CDCl₃, 200 MHz) δ = 23.0, 2.3. HRMS (ESI): m/z calcd for C₄₁H₃₁AuNO₄P₂+ 860.1388 [M+MeCN-NTf₂⁻]+, found, 860.1387. [α]_p = +28 (c 1.83, CHCl₃).

3. Synthesis of enones 8 and indole 9

Synthesis of 2-iodocyclohex-2-en-1-one (SI-3) ⁴



To a stirred solution of cyclohex-2-en-1-one (4.05 mL, 42 mmol, 1.0 equiv.) in a 1:1 mixture of THF-H₂O (200 mL) was added K₂CO₃ (6.9 g, 50 mmol, 1.2 equiv.), I₂ (15.9 g, 63 mmol, 1.5 equiv.) and 4-dimethylaminopyridine (DMAP) (1.02 g, 8.3 mmol, 0.2 equiv.) successively. Then the reaction was stirred at room temperature for 2 h. Upon completion, the reaction solution mixture was diluted with ethyl acetate and washed with saturated aqueous Na₂S₂O₃ and aqueous 0.1 M HCl successively. The mixture was subsequently extracted with ethyl acetate and dried over MgSO₄. Crude product was purified by flash column chromatography (heptane to 20 % EtOAc-Heptane), giving product **SI-3** as a white solid (7.17 g, 32 mmol, 77 %).

Synthesis of 2-iodocyclopent-2-en-1-one^{4, 5} (SI-4)

Compound SI-4 was prepared by following the general procedure for the synthesis of SI-3. To a stirred solution of cyclopent-2-en-1-one (0.42 mL, 5 mmol, 1.0 equiv.) in a 1:1 mixture of THF-H₂O (30 mL) was

⁴ (a) T. Yao; Zhang, X.; Larock, R. C. *J. Am. Chem. Soc.* **2004**, *126*, 11164-11165; (b) M. Krafft; Cran, J. Synlett **2005**, 1263-1266; (c) L.-E. Harim; Moises, R.-O.; F., O. H. *Eur. J. Org. Chem.* **2016**, 51-54.

⁵ H. Sundén; Schäfer, A.; Scheepstra, M.; Leysen, S.; Malo, M.; Ma, J.-N.; Burstein, E. S.; Ottmann, C.; Brunsveld, L.; Olsson, R. *J. Med. Chem.* **2016**, *59*, 1232-1238.

added K_2CO_3 (0.83 g, 6 mmol, 1.2 equiv.), I_2 (1.9 g, 7.5 mmol, 1.5 equiv.) and 4-dimethylaminopyridine (DMAP) (0.13 g, 1 mmol, 0.2 equiv.) successively. Then the reaction was stirred at room temperature for 2 h. Upon completion, the reaction solution mixture was diluted with ethyl acetate and washed with saturated aqueous $Na_2S_2O_3$ and aqueous 0.1 M HCl successively. The mixture was subsequently extracted with ethyl acetate and dried over MgSO₄. Crude product was purified by flash column chromatography (heptane to 20 % EtOAc-Heptane), giving product **SI-4** as a pale yellow solid (0.57 g, 2.7 mmol, 55 %).

Synthesis of 2-iodocyclohept-2-en-1-one^{4, 5} (SI-5)



Compound **SI-5** was prepared by following the general procedure for the synthesis of **SI-3**. To a stirred solution of cyclopent-2-en-1-one (0.34 mL, 3.0 mmol, 1.0 equiv.) in a 1:1 mixture of THF-H₂O (14 mL) was added K₂CO₃ (0.50 g, 3.6 mmol, 1.2 equiv.), I₂ (1.14 g, 4.5 mmol, 1.5 equiv.) and 4-dimethylaminopyridine (DMAP) (0.08 g, 0.6 mmol, 0.2 equiv.) successively. Then the reaction was stirred at room temperature for 2 h. Upon completion, the reaction solution mixture was diluted with ethyl acetate and washed with saturated aqueous Na₂S₂O₃ and aqueous 0.1 M HCl successively. The mixture was subsequently extracted with ethyl acetate and dried over MgSO₄. Crude product was purified by flash column chromatography (heptane to 20 % EtOAc-Heptane), giving product **SI-5** as a pale yellow oil (0.37 g, 1.6 mmol, 52 %).

Synthesis of 2-(phenylethynyl)cyclohex-2-en-1-one⁴ (8a)



A solution of 2-iodo-cyclohexenone (430.0 mg, 1.94 mmol, 1.0 equiv.) in THF (5.1 mL) was treated with $PdCl_2(PPh_3)_2$ (69.0 mg, 0.1 mmol, 5 mol %) and Cul (37.0 mg, 0.19 mmol, 10 mol %) and cooled down to 0 °C under an Ar atmosphere and in the dark. After 10 min of stirring, phenylacetylene (0.44 mL, 409.2 mg, 4.01 mmol) and diisopropyl amine (0.82 mL, 59.0 mg, 5.85 mmol) were added, and the resulting yellow to dark brown solution was stirred at 0 °C. The reaction mixture was partitioned between CH_2Cl_2 and 0.5 N aqueous HCl solution. The aqueous layer was extracted three times with CH_2Cl_2 and the combined organic phases were washed with brine, dried over MgSO₄, filtered and concentrated under vacuum. The crude product was purified by flash column chromatography to yield alkyne **8a** as a yellow solid (334 mg, 1.75 mmol, 88 %).

Synthesis of 2-(phenylethynyl)cyclohex-2-en-1-one⁶ (8b)



⁶ Rauniyar, V.; Wang, Z. J.; Burks, H. E.; Toste, F. D., J. Am. Chem. Soc. 2011, 133, 8486-8489.

Compound **8b** was prepared by following the general procedure for the synthesis of **8a**. A solution of 2-iodo-cyclohexenone (444.0 mg, 2 mmol, 1.0 equiv.) in THF (5 mL) was treated with $PdCl_2(PPh_3)_2$ (70.2 mg, 0.1 mmol, 5 mol %) and Cul (38.1 mg, 0.2 mmol, 10 mol %) and cooled down to 0 °C under an Ar atmosphere. After 10 min of stirring, 1-ethynyl-4-methoxybenzene (528.6 mg, 4 mmol, 2 equiv.) and diisopropyl amine (0.87 mL, 627.4 mg, 6.2 mmol) were added, and the resulting solution was stirred at 0 °C. The reaction mixture was partitioned between CH_2Cl_2 and 0.5 N aqueous HCl solution. The aqueous layer was extracted three times with CH_2Cl_2 and the combined organic phases were washed with brine, dried over MgSO₄, filtered and concentrated under vacuum. The crude product was purified by flash column chromatography to yield alkyne **8b** as a brown solid (148.7 mg, 0.66 mmol, 33 %).

Synthesis of 2-(phenylethynyl)cyclohex-2-en-1-one⁵ (8c)



Compound **8c** was prepared by following the general procedure for the synthesis of **8a**. A solution of 2-iodo-cyclohexenone (444.0 mg, 2 mmol, 1.0 equiv.) in THF (5 mL) was treated with $PdCl_2(PPh_3)_2$ (70.2 mg, 0.1 mmol, 5 mol %) and Cul (38.1 mg, 0.2 mmol, 10 mol %) and cooled down to 0 °C under an Ar atmosphere. After 10 min of stirring, 1-ethynyl-4-methylbenzene (464.6 mg, 4 mmol, 2 equiv.) and diisopropyl amine (0.87 mL, 627.4 mg, 6.2 mmol) were added, and the resulting solution was stirred at 0 °C. The reaction mixture was partitioned between CH_2Cl_2 and 0.5 N aqueous HCl solution. The aqueous layer was extracted three times with CH_2Cl_2 and the combined organic phases were washed with brine, dried over MgSO₄, filtered and concentrated under vacuum. The crude product was purified by flash column chromatography to yield alkyne **8c** as a gray solid (313.9 mg, 1.49 mmol, 75 %).

Synthesis of 2-(phenylethynyl)cyclohex-2-en-1-one (8d)⁷



Compound **8d** was prepared by following the general procedure for the synthesis of **8a**. A solution of 2-iodo-cyclohexenone (444.0 mg, 2 mmol, 1.0 equiv.) in THF (5 mL) was treated with $PdCl_2(PPh_3)_2$ (70.2 mg, 0.1 mmol, 5 mol %) and Cul (38.1 mg, 0.2 mmol, 10 mol %) and cooled down to 0 °C under an Ar atmosphere. After 10 min of stirring, 1-ethynyl-4-methoxybenzene (528.6 mg, 4 mmol, 2 equiv.) and diisopropyl amine (0.87 mL, 627.4 mg, 6.2 mmol) were added, and the resulting solution was stirred at 0 °C. The reaction mixture was partitioned between CH_2Cl_2 and 0.5 N aqueous HCl solution. The aqueous layer was extracted three times with CH_2Cl_2 and the combined organic phases were washed with brine, dried over MgSO₄, filtered and concentrated under vacuum. The crude product was purified by flash column chromatography to yield alkyne **8d** as a brown solid (366.6 mg, 1.62 mmol, 53 %).

⁷ Cho, C.-H.; Larock, R. C. ACS Comb. Sci. 2011, 13, 272-279.

Synthesis of 2-(Heptane-1-yn-1-yl)cyclohex-2-en-1-one (8e)⁸



Compound **8e** was prepared by following the general procedure for the synthesis of **8a**. A solution of 2-iodo-cyclohexenone (444 mg, 2 mmol, 1.0 equiv.) in THF (6 mL) was treated with $PdCl_2(PPh_3)_2$ (70.2 mg, 0.1 mmol, 5 mol %) and Cul (38.1 mg, 0.2 mmol, 10 mol %) and cooled down to 0 °C under Ar atmosphere and in the dark. After 10 min of stirring, Hept-1-yne (0.53 mL, 4.0 mmol, 2 equiv.) and diisopropyl amine (0.83 mL, 6.3 mmol, 3.1 equiv.) were added, and the resulting yellow to dark brown solution was stirred from 0 °C. The reaction mixture was partitioned between CH_2Cl_2 and 1.0 N aqueous HCl solution. The aqueous layer was extracted three times with CH_2Cl_2 and the combined organic phases were washed with brine, dried over MgSO₄, filtered and concentrated under vacuum. The crude product was purified by flash column chromatography to yield product **8e** as a white solid (231.9 mg, 1.2 mmol, 59 %).

Synthesis of 2-(phenylethynyl)cyclopent-2-en-1-one⁹ (8f)



Compound **8f** was prepared by following the general procedure for the synthesis of **8a**. A solution of 2-iodocyclopent-2-en-1-one (186 mg, 0.89 mmol, 1.0 equiv.) in THF (3 mL) was treated with $PdCl_2(PPh_3)_2$ (31.4 mg, 0.04 mmol, 5 mol %) and Cul (17.1 mg, 0.09 mmol, 10 mol %) and cooled down to 0 °C under Ar atmosphere and in the dark. After 10 min of stirring, phenylacetylene (0.2 mL, 1.79 mmol, 2 equiv.) and diisopropyl amine (0.39 mL, 2.77 mmol, 3.1 equiv.) were added, and the resulting yellow to dark brown solution was stirred from 0 °C. The reaction mixture was partitioned between CH_2Cl_2 and 1.0 N aqueous HCl solution. The aqueous layer was extracted three times with CH_2Cl_2 and the combined organic phases were washed with brine, dried over MgSO₄, filtered and concentrated under vacuum. The crude product was purified by flash column chromatography to yield product **8f** as a pale yellow solid (156.7 mg, 0.86 mmol, 97 %).

Synthesis of 2-(phenylethynyl)cyclohept-2-en-1-one⁹ (8g)



Compound **8g** was prepared by following the general procedure for the synthesis of **8a**. A solution of 2-iodocyclopent-2-en-1-one (219.3 mg, 0.93 mmol, 1.0 equiv.) in THF (3 mL) was treated with PdCl₂(PPh₃)₂

⁸ (a) Salacz, L.; Girard, N.; Suffert, J.; Blond, G. *Molecules* **2019**, *24*, 595. (b) Salacz, L.; Girard, N.; Blond, G.; Suffert, J. Org. Lett. **2018**, *20*, 3915-3918.

⁹ T. Yao; Zhang, X.; Larock, R. C. J. Org. Chem. **2005**, 70, 7679-7685.

(312.6 mg, 0.05 mmol, 5 mol %) and CuI (17.7 mg, 0.09 mmol, 10 mol %) and cooled down to 0 °C under Ar atmosphere and in the dark. After 10 min of stirring, phenylacetylene (0.21 mL, 1.86 mmol, 2 equiv.) and diisopropyl amine (0.41 mL, 2.88 mmol, 3.1 equiv.) were added, and the resulting yellow to dark brown solution was stirred from 0 °C. The reaction mixture was partitioned between CH_2Cl_2 and 1.0 N aqueous HCl solution. The aqueous layer was extracted three times with CH_2Cl_2 and the combined organic phases were washed with brine, dried over MgSO₄, filtered and concentrated under vacuum. The crude product was purified by flash column chromatography to yield product **8g** as a pale yellow oil (188.0 mg, 0.89 mmol, 96 %).

Synthesis of 1-benzyl-1H-indole¹⁰ (9g)



To a stirring solution of indole (352.5 mg, 3 mmol, 1 equiv.) in dry DMF (3 mL), NaH (144.0 mg, 3.6 mmol, 1.2 equiv.) was added portionwise under N₂ at 0 °C. The reaction mixture was then warmed to room temperature and stirred for 30 min. After cooling to 0 °C, BnBr (564.5 mg, 3.3 mmol, 1.1 equiv.) (1.2 mL) was added dropewise to the reaction mixture. The resulting mixture was stirred at room temperature overnight. The reaction was quenched with water and extracted three times with ethyl acetate, the combined organic phases were dried over MgSO₄, filtered and concentrated under vacuum. The crude product was purified by flash column chromatography to yield product **9g** as pale yellow oil (553.4 mg, 2.67 mmol, 89 %).

Synthesis of 1,3-dimethyl-1H-indole¹¹ (9i)



To a stirring solution of 60 % NaH (240 mg, 6 mmol, 2 equiv.) in dry DMF (2.4 mL), 3-methylindole (393.5 mg, 3 mmol, 1 equiv.) in DMF (2.4) was added dropwise at 0 °C. The mixture was allowed to warm to room temperature and stirred for 30 min. After cooling to 0 °C, a solution of MeI (0.38 mL, 6 mmol, 2 equiv.) in DMF (1.2 mL) was added dropewise. The resulting mixture was stirred at room temperature overnight. The reaction was quenched with water and extracted three times with ethyl acetate, the combined organic phases were dried over MgSO₄, filtered and concentrated under vacuum. The crude product was purified by flash column chromatography to yield product **9i** as a clear oil (426.9 mg, 2.94 mmol, 98 %).

¹⁰ K. Nemoto; Tanaka, S.; Konno, M.; Onozawa, S.; Chiba, M.; Tanaka, Y.; Sasaki, Y.; Okubo, R.; Hattori, T. Tetrahedron 2016, 72, 734-745.

¹¹ C. Shao; Shi, G.; Zhang, Y.; Pan, S.; Guan, X. Org. Lett. 2015, 17, 2652-2655.

Synthesis of 3-isopropyl-1H-indole¹² (9k)



In a oven dried flask, triethylsilane (5.78 mL, 36.0 mmol, 2.4 equiv.) and trichloroacetic acid (2.26 g, 22.5 mmol, 1.5 equiv.) were dissolved in toluene (7.50 mL) and the resulting solution was heated to 70 °C. A solution of indole (1.76 g, 15.0 mmol, 1 equiv.) and acetone (1.23 mL, 16.5 mmol, 1.1 equiv.) in toluene (7.50 mL) were then added over 1 h. After an additional 20 min at 70 °C the solution was quenched with 10% aqueous solution of sodium carbonate, the organic layer was separated, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by column chromatography to afford indole **9k** (1.61 g, 10.1 mmol, 67%) as a colorless solid.

¹² Y. Zhang; Stephens, D.; Hernandez, G.; Mendoza, R.; Larionov, O. V. Chem. Eur. J. **2012**, *18*, 16612-16615.

4. Investigation with respect to the protocol for the activation of the catalysts

5 and SI-2 and the silver salts used



Protocol A: In situ activation of the active catalyst with the silver salt in the presence of all components of the reaction.

Protocol B: Activation of the active catalyst with the silver salt in CDCl₃, filtration of the solution and use of the solution.

Protocol C: Formation of the active catalyst in CDCl₃, filtration of the solution, evaporation and use of the resulting solid as the catalyst.

| entry | LAuCl | AgX (mol%) | Actual catalyst | Yield (%) | ee (%) | protocol |
|-------|---------------|---------------------------------------|-----------------|-----------|--------|----------|
| 1 | (S)- 5 | Ag ₂ CO ₃ (0.1) | 6 | 75 | 96 | А |
| 2 | (S)- 5 | Ag ₂ CO ₃ (0.1) | 6 | 61 | 79 | В |
| 3 | (S)- 5 | Ag ₂ CO ₃ (0.1) | 6 | 65 | 26 | С |
| 4 | (S)- 5 | AgNTf ₂ (0.2) | 7a | 71 | 7 | А |
| 5 | (S)- 5 | AgNTf ₂ (0.2) | 7a | 85 | 29 | В |
| 6 | (S)- 5 | $AgNTf_2(0.2)$ | 7a | 80 | 60 | С |
| 7 | (S)- 5 | AgSbF ₆ (0.2) | 7b | 85 | 47 | А |
| 8 | (S)- 5 | $AgSbF_6(0.2)$ | 7b | 76 | 62 | В |
| 9 | (S)- 5 | AgSbF ₆ (0.2) | 7b | 93 | 67 | С |
| 10 | SI-2 | AgNTf ₂ (0.2) | 11a | 85 | 15 | В |
| 11 | SI-2 | $AgSbF_6(0.2)$ | 11b | 90 | 12 | В |

Experiments highlighted in grey are those reported within the manuscript.

5. Scope of the reaction



To a flask was added 2-(1-alkynyl)-2-alken-1-one (0.55 mmol, 1.1 equiv.), Nucleophile (NuH, 0.5 mmol, 1.0 equiv.), **(S)-5** (0.001 mmol, 0.2 mol %), Ag_2CO_3 (0.0005 mmol, 0.1 mol %) and toluene (2.5 mL). The resulting mixture was then stirred overnight at room temperature. The solvent was then removed under vacuum and the residue was purified by flash column chromatography.

(R)-3-(2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-1H-indole (10aa)



Compound **10aa** was prepared according to the general procedure from **8a** (107.9 mg, 0.55 mmol, 1.1 equiv.), **9a** (58.8 mg, 0.5 mmol, 1.0 equiv.), **(S)-5** (0.8 mg, 0.001 mmol, 0.2 mol %) and Ag₂CO₃ (0.1 mg, 0.0005 mmol, 0.1 mol %) in toluene (2.5 mL), yielding product **10aa** (116.5 mg, 0.37 mmol, 75 %) as a white solid for which the spectroscopical data correspond to those reported in the literature.¹³ [α]_D = +38 (*c* 0.89, CHCl₃). ee = 96 %, determined on a Chiralpak IA column (heptane:IPA = 95:5, 1 mL/min), retention times: T_R (minor): 19.7 min, T_R (major): 25.6 min.

10aa was alternatively obtained from the same protocol in the absence of Ag_2CO_3 in 80% yield and 92% ee.

m.p.: 158.8-160.3 °C.. ¹**H NMR (CDCl₃, 500 MHz)** δ = 7.89 (s, 1H), 7.62 (d, *J* = 7.6 Hz, 1H), 7.59 (d, *J* = 7.6 Hz, 2H), 7.36 (d, *J* = 7.9 Hz, 1H), 7.33-7.30 (m, 2H), 7.22-7.16 (m, 2H), 7.11 (t, *J* = 7.3 Hz, 1H), 6.86 (d, *J* = 1.8 Hz, 1H), 6.44 (s, 1H), 4.25 (br, 1H), 2.76-2.75 (m, 2H), 2.18-2.13 (m, 1H), 1.98-1.93 (m, 2H), 1.88-1.84 (m, 1H). **HRMS (ESI)**: m/z: calcd for C₂₂H₂₀NO⁺ 314.1539 [M+H]⁺, found, 314.1543.

 ¹³ (a) G. Force; Ki, Y. L. T.; Isaac, K.; Retailleau, P.; Marinetti, A.; Betzer, J.-F. Adv. Synth. Catal. 2018, 360, 3356-3366; (b) V. Rauniyar; Wang, Z. J.; Burks, H. E.; Toste, F. D. J. Am. Chem. Soc. 2011, 133, 8486-8489.

(R)-5-methoxy-3-(2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-1H-indole (10ab)



Yield: 81 %, ee: 97 %.

Compound **10ab** was prepared according to the general procedure from **8a** (107.9 mg, 0.55 mmol, 1.1 equiv.), **9c** (73.6 mg, 0.5 mmol, 1.0 equiv.), **(S)-5** (0.8 mg, 0.001 mmol, 0.2 mol %) and Ag₂CO₃ (0.1 mg, 0.0005 mmol, 0.1 mol %) in toluene (2.5 mL), yielding product **10ab** (138.2 mg, 0.40 mmol, 81 %) as a white solid for which the spectroscopical data correspond to those reported in the literature.¹³ [α]_D = -7 (*c* 0.98, CHCl₃). ee = 97%, determined on a Chiralpak IA column (heptane:IPA = 95:5, 1 mL/min), retention times: T_R (minor): 29.2 min, T_R (major): 41.4 min.

10ab was alternatively obtained from the same protocol in the absence of Ag_2CO_3 in 73% yield and 94% ee.

¹H NMR (CDCl₃, 500 MHz) δ = 7.79 (s, 1H), 7.58 (d, *J* = 7.6 Hz, 2H), 7.31 (t, *J* = 7.6 Hz, 2H), 7.23 (d, *J* = 8.2 Hz, 1H), 7.17 (t, *J* = 7.3 Hz, 1H), 7.06 (s, 1H), 6.86 (d, *J* = 8.5 Hz, 1H), 6.81 (s, 1H), 6.44 (s, 1H), 4.20 (t, *J* = 5.2 Hz, 1H), 3.84 (s, 3H), 2.80-2.71 (m, 2H), 2.16-2.11 (m, 1H), 1.98-1.90 (m, 2H), 1.87-1.82 (m, 1H). HRMS (ESI): *m/z*: calculated for C₂₃H₂₂NO₂⁺: 344.1645 [M+H]⁺, found, 344.1646.

(R)-5-bromo-3-(2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-1H-indole (10ac)



Yield: 77 %, ee: 97 %.

Compound **10ac** was prepared according to the general procedure from **8a** (107.9 mg, 0.55 mmol, 1.1 equiv.), **9d** (98.0 mg, 0.5 mmol, 1.0 equiv.), **(S)-5** (0.8 mg, 0.001 mmol, 0.2 mol %) and Ag₂CO₃ (0.1 mg, 0.0005 mmol, 0.1 mol %) in toluene (2.5 mL), yielding product **10ac** (150.9 mg, 0.39 mmol, 77 %) as a white solid for which the spectroscopical data correspond to those reported in the literature.¹³ [α]_D = -10 (*c* 1.02, CHCl₃). ee = 97%, determined on a Chiralpak IA column (heptane:IPA = 95:5, 1 mL/min), retention times: T_R (minor): 19.4 min, T_R (major): 26.7 min.

10ac was alternatively obtained from the same protocol in the absence of Ag_2CO_3 in 30% yield and 75% ee.

¹H NMR (CDCl₃, 300 MHz) δ = 7.93 (s, 1H), 7.74 (d, J = 1.3 Hz, 1H), 7.60-7.57 (m, 2H), 7.34-7.16 (m,

5H), 6.83 (d, *J* = 2.3 Hz, 1H), 6.40 (s, 1H), 4.17 (t, *J* = 5.5 Hz, 1H), 2.76-2.73 (m, 2H), 2.19-2.07 (m, 1H), 1.96-1.79 (m, 3H). **HRMS (ESI)**: *m/z*: calculated for C₂₂H₁₉BrNO⁺: 392.0645 [M+H]⁺, found, 392.0638.

(R)-6-methyl-3-(2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-1H-indole (10ad)



Yield: 44 %, ee: 96 %

Compound **10ad** was prepared according to the general procedure from **8a** (21.6 mg, 0.11 mmol, 1.1 equiv.), **9e** (13.1 mg, 0.1 mmol, 1.0 equiv.), **(S)-5** (0.2 mg, 0.0002 mmol, 0.2 mol %) and Ag_2CO_3 (0.1 mg, 0.0001 mmol, 0.1 mol %) in toluene (2.5 mL), yielding product **10ad** (14.4 mg, 0.04 mmol, 44 %) as a white solid for which the spectroscopical data correspond to those reported in the literature.¹³

 $[\alpha]_{D}$ = +28 (*c* 1.21, CHCl₃). ee = 96%, determined on a Chiralpak IA column (heptane:IPA = 95:5, 1 mL/min), retention times: T_R (minor): 19.5 min, T_R (major): 22.4 min. ¹H NMR (CDCl₃, 500 MHz) δ = 7.71 (s, 1H), 7.57 (d, *J* = 7.9 Hz, 2H), 7.48 (d, *J* = 7.9 Hz, 1H), 7.30 (t, *J* = 7.6 Hz, 2H), 7.18-7.12 (m, 2H), 6.93 (d, *J* = 7.9 Hz, 1H), 6.75 (s, 1H), 6.42 (s, 1H), 4.20 (br, 1H), 2.76-2.73 (m, 2H), 2.45 (s, 3H), 2.15-2.10 (m, 1H), 1.98-1.90 (m, 2H), 1.86-1.83 (m, 1H). HRMS (ESI): *m/z*: calculated for C₂₃H₂₂NO⁺: 328.1696 [M+H]⁺, found, 328.1696.

(R)-2-methyl-3-(2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-1H-indole (10ae)



Compound **10ae** was prepared according to the general procedure from **8a** (107.9 mg, 0.55 mmol, 1.1 equiv.), **9f** (65.6 mg, 0.5 mmol, 1.0 equiv.), **(S)-5** (0.8 mg, 0.001 mmol, 0.2 mol %) and Ag_2CO_3 (0.1 mg, 0.0005 mmol, 0.1 mol %) in toluene (2.5 mL), yielding product **10ae** (80.0 mg, 0.24 mmol, 49 %) as a white solid for which the spectroscopical data correspond to those reported in the literature.¹³

 $[\alpha]_{D}$ = +26 (*c* 1.20, CHCl₃). ee = 82 %, determined on a Chiralpak AD-H column (heptane:IPA = 90:10, 1 mL/min), retention times: T_R (minor): 4.3 min, T_R (major): 5.3 min. ¹H NMR (CDCl₃, 500 MHz) δ = 7.69 (s, 1H), 7.54 (d, *J* = 7.9 Hz, 2H), 7.30-7.24 (m, 4H), 7.15 (t, *J* = 7.3 Hz, 1H), 7.06 (t, *J* = 7.3 Hz, 1H), 6.94 (t, *J* = 7.6 Hz, 1H), 6.28 (s, 1H), 4.14 (br, 1H), 2.82 (br, 2H), 2.31 (s, 3H), 2.11-2.04 (m, 2H), 1.96-1.88 (m, 2H). HRMS (ESI): *m/z*: calculated for C₂₃H₂₂NO⁺: 328.1696 [M+H]⁺, found, 328.1691.

(R)-1-methyl-3-(2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-1H-indole (10af)



Compound **10af** was prepared according to the general procedure from **8a** (107.9 mg, 0.55 mmol, 1.1 equiv.), **9b** (65.6 mg, 0.5 mmol, 1.0 equiv.), **(S)-5** (0.8 mg, 0.001 mmol, 0.2 mol %) and Ag_2CO_3 (0.1 mg, 0.0005 mmol, 0.1 mol %) in toluene (2.5 mL), yielding product **10af** (150.2 mg, 0.46 mmol, 92 %) as a white solid for which the spectroscopical data correspond to those reported in the literature.^{13, 4a}

[α]_D = -5 (*c* 0.78, CHCl₃). ee: 94 %, determined on a Chiralpak IC column (heptane:IPA = 95:05, 1 mL/min), retention times: T_R (minor): 4.7 min, T_R (major): 5.1 min. ¹H NMR (CDCl₃, 500 MHz) δ = 7.60 (t, *J* = 7.6 Hz, 3H), 7.33-7.29 (m, 3H), 7.24-7.21 (m, 1H), 7.18 (t, *J* = 7.3 Hz, 1H), 7.10 (t, *J* = 7.3 Hz, 1H), 6.72 (s, 1H), 6.44 (s, 1H), 4.24 (t, *J* = 5.5 Hz, 1H), 3.71 (s, 3H), 2.76-2.75 (m, 2H), 2.16-2.12 (m, 1H), 1.97-1.91 (m, 2H), 1.87-1.84 (m, 1H). HRMS (ESI): m/z: calcd for C₂₃H₂₂NO⁺ 328.1696 [M+H]⁺, found, 328.1696.

(R)-1-benzyl-3-(2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-1H-indole (10ag)



Yield: 83 %, ee: 92 %.

Compound **10ag** was prepared according to the general procedure from **8a** (21.6 mg, 0.11 mmol, 1.1 equiv.), **9g** (20.7 mg, 0.1 mmol, 1.0 equiv.), **(S)-5** (0.2 mg, 0.0002 mmol, 0.2 mol %) and Ag_2CO_3 (0.1 mg, 0.0001 mmol, 0.1 mol %) in toluene (0.5 mL), yielding product **10ag** (33.3 mg, 0.08 mmol, 83 %) as a pale yellow solid

 $[\alpha]_{D}$ = +34 (*c* 1.00, CHCl₃). ee: 92 %, determined on a Chiralpak IA column (heptane:IPA = 95:05, 1 mL/min), retention times: T_R (major): 6.5 min, T_R (minor): 11.3 min. ¹H NMR (CDCl₃, 500 MHz) δ = 7.54 (d, *J* = 7.6 Hz, 1H), 7.49 (d, *J* = 7.9 Hz, 2H), 7.23-7.13 (m, 6H), 7.08 (t, *J* = 7.6 Hz, 2H), 7.02-7.97 (m, 3H), 6.73 (s, 1H), 6.35 (s, 1H), 5.14 (dd, *J*₁ = 21.3 Hz, *J*₂ = 16.2 Hz, 2H), 4.17 (t, *J* = 6.1 Hz, 1H), 2.68-2.64 (m, 2H), 2.10-2.05 (m, 1H), 1.90-1.84 (m, 2H), 1.80-1.73 (m, 1H). ¹³C NMR (CDCl₃, 125 MHz) δ = 151.9, 151.4, 138.0, 137.2, 131.6, 128.9, 128.7, 127.7, 127.6, 126.9, 126.8, 126.6, 123.5, 122.4, 121.9, 119.6, 119.6, 119.2, 110.0, 106.3, 50.2, 31.6, 31.1, 23.6, 21.4. HRMS (ESI): *m/z*: calcd for C₂₉H₂₄NO⁺ 402.1852 [M+H-H₂]⁺, found, 402.1858.

(R)-3-(2-(4-methoxyphenyl)-4,5,6,7-tetrahydrobenzofuran-4-yl)-1H-indole (10ba)



Compound **10ba** was prepared according to the general procedure from **8b** (24.9 mg, 0.11 mmol, 1.1 equiv.), **9a** (11.7 mg, 0.1 mmol, 1.0 equiv.), **(S)-5** (0.2 mg, 0.0002 mmol, 0.2 mol %) and Ag_2CO_3 (0.1 mg, 0.0001 mmol, 0.1 mol %) in toluene (0.5 mL), yielding product **10ba** (29.8 mg, 0.09 mmol, 87 %) as a pale yellow solid for which the spectroscopical data correspond to those reported in the literature.¹³

 $[\alpha]_{D}$ = +11 (*c* 1.90, CHCl₃). ee = 91 %, determined on a Chiralpak IC column (heptane:IPA = 95:5, 1 mL/min), retention times: T_R (minor): 9.5 min, T_R (major): 10.5 min. ¹H NMR (CDCl₃, 500 MHz) δ = 7.89 (s, 1H), 7.62 (d, *J* = 7.9 Hz, 1H), 7.51 (d, *J* = 8.5 Hz, 2H), 7.34 (d, *J* = 7.9 Hz, 1H), 7.19 (t, *J* = 7.6 Hz, 1H), 7.10 (t, *J* = 7.6 Hz, 1H), 6.86-6.84 (m, 3H), 6.29 (s, 1H), 4.24-4.22 (m, 1H), 3.79 (s, 3H), 2.75-2.72 (m, 2H), 2.61-2.11 (m, 1H), 1.98-1.91 (m, 2H), 1.86-1.81 (m, 1H). HRMS (ESI): *m/z*: calculated for C₂₃H₂₂NO₂⁺: 344.1645 [M+H]⁺, found, 344.1645.

(R)-3-(2-(p-tolyl)-4,5,6,7-tetrahydrobenzofuran-4-yl)-1H-indole (10ca)



Compound **10ca** was prepared according to the general procedure from **8c** (23.1 mg, 0.11 mmol, 1.1 equiv.), **9a** (11.7 mg, 0.1 mmol, 1.0 equiv.), **(S)-5** (0.2 mg, 0.0002 mmol, 0.2 mol %) and Ag_2CO_3 (0.1 mg, 0.0001 mmol, 0.1 mol %) in toluene (0.5 mL), yielding product **10ca** (31.0 mg, 0.09 mmol, 95 %) as a pale yellow solid for which the spectroscopical data correspond to those reported in the literature.¹³

 $[\alpha]_{D}$ = +68 (*c* 1.01, CHCl₃). ee = 95 %, determined on a Chiralpak IC column (heptane:IPA = 95:5, 1 mL/min), retention times: T_R (minor): 6.3 min, T_R (major): 7.2 min. ¹H NMR (CDCl₃, 500 MHz) δ = 7.71 (s, 1H), 7.52 (d, *J* = 7.9 Hz, 1H), 7.38 (d, *J* = 7.9 Hz, 2H), 7.21 (d, *J* = 8.2 Hz, 1H), 7.09 (t, *J* = 7.6 Hz, 1H), 7.03-7.00 (m, 3H), 6.70-6.69 (m, 1H), 6.27 (s, 1H), 4.13 (t, *J* = 5.5 Hz, 1H), 2.66-2.63 (m, 2H), 2.22 (s, 3H), 2.06-2.01 (m, 1H), 1.86-1.81 (m, 2H), 1.76-1.71 (m, 1H). HRMS (ESI): *m/z*: calculated for C₂₃H₂₀NO⁺: 326.1539 [M+H-H₂]⁺, found, 326.1537.

(R)-3-(2-(3-methoxyphenyl)-4,5,6,7-tetrahydrobenzofuran-4-yl)-1H-indole (10da)



Yield : 77 %, ee : 84 %.

Compound **10da** was prepared according to the general procedure from **8d** (24.9 mg, 0.11 mmol, 1.1 equiv.), **9a** (11.7 mg, 0.1 mmol, 1.0 equiv.), **(S)-5** (0.2 mg, 0.0002 mmol, 0.2 mol %) and Ag_2CO_3 (0.1 mg, 0.0001 mmol, 0.1 mol %) in toluene (0.5 mL), yielding product **10da** (26.4 mg, 0.08 mmol, 77 %) as a pale yellow solid.

[α]_D = +15 (*c* 1.29, CHCl₃). ee = 84 %, determined on a Chiralpak IA column (heptane:IPA = 90:10, 1 mL/min), retention times: T_R (minor): 12.1 min, T_R (major): 23.7 min. ¹H NMR (CDCl₃, 500 MHz) δ = 7.92 (s, 1H), 7.61 (d, *J* = 7.9 Hz, 1H), 7.36 (d, *J* = 8.2 Hz, 1H), 7.24-7.09 (m, 5H), 6.86 (d, *J* = 1.8 Hz, 1H), 6.74 (dd, *J*₁ = 7.9 Hz, *J*₂ = 1.8 Hz, 1H), 6.43 (s, 1H), 4.25 (t, *J* = 5.5 Hz, 1H), 3.82 (s, 3H), 2.78-2.74 (m, 2H), 2.18-2.13 (m, 1H), 1.98-1.92 (m, 2H), 1.88-1.82 (m, 1H). ¹³C NMR (CDCl₃, 125 MHz) δ = 136.8, 132.9, 129.8, 126.9, 122.4, 122.3, 122.2, 120.5, 119.5, 119.4, 116.1, 112.9, 111.4, 108.6, 106.6, 160.1, 151.7, 151.5, 55.5, 31.4, 31.1, 23.6, 21.4. HRMS (ESI): *m/z*: calculated for $C_{23}H_{22}NO_2^+$: 344.1645 [M+H]⁺, found, 344.1641.

(R)-3-(2-pentyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-1H-indole (10ea)



Yield: 46 %, ee: 87 %.

Compound **10ea** was prepared according to the general procedure from **8e** (20.9 mg, 0.11 mmol, 1.1 equiv.), **9a** (11.7 mg, 0.1 mmol, 1.0 equiv.), **(S)-5** (0.8 mg, 0.001 mmol, 1 mol %) and Ag_2CO_3 (0.1 mg, 0.0005 mmol, 0.5 mol %) in toluene (0.5 mL), yielding product **10ea** (14 mg, 0.05 mmol, 46 %) as a white solid.

[α]_D = +2 (*c* 0.14, CHCl₃). ee = 87 %, determined on a Chiralpak IA column (heptane:IPA = 95:5, 1 mL/min), retention times: T_R (minor): 8.7 min, T_R (major): 10.5 min. ¹H NMR (CDCl₃, 500 MHz) δ = 7.88 (bs, 1H), 7.59 (d, *J* = 7.9 Hz, 1H), 7.34 (d, *J* = 7.9 Hz, 1H), 7.18 (t, *J* = 7.6 Hz, 1H), 7.09 (t, *J* = 7.6 Hz, 1H), 6.83 (s, 1H), 5.74 (s, 1H), 4.17 (t, *J* = 5.5 Hz, 1H), 2.67-2.60 (m, 2H), 2.54 (t, *J* = 7.6 Hz, 2H), 2.14-2.09 (m, 1H), 1.94-1.86 (m, 2H), 1.82-1.76 (m, 1H), 1.62-1.57 (m, 2H), 1.32-1.28 (m, 4H), 0.88 (t, *J* = 6.7 Hz, 3H). ¹³C NMR (CDCl₃, 125 MHz) δ = 154.4, 149.2, 136.8, 127.0, 122.2, 122.1, 120.8, 120.4, 119.5, 119.3, 111.3, 105.6, 31.7, 31.5, 31.1, 28.4, 28.2, 23.5, 22.6, 21.5, 14.2. HRMS (ESI): *m/z*: calculated for C₂₁H₂₄NO⁺: 306.1852 [M+H-H₂]⁺, found, 306.1857.

(R)-3-(2-phenyl-5,6-dihydro-4H-cyclopenta[b]furan-4-yl)-1H-indole (10fa)



Compound **10fa** was prepared according to the general procedure from **8f** (20.1 mg, 0.11 mmol, 1.1 equiv.), **9a** (11.7 mg, 0.1 mmol, 1.0 equiv.), **(S)-5** (1.7 mg, 0.002 mmol, 2 mol %) and Ag_2CO_3 (0.3 mg, 0.001 mmol, 1 mol %) in toluene (0.5 mL), yielding product **10fa** (16.4 mg, 0.06 mmol, 55 %) as a white solid.

[α]_D = -18 (*c* 0.75, CHCl₃). ee = 21 %, determined on a Chiralpak IA column (heptane:IPA = 95:05, 1 mL/min), retention times: T_R (major): 26.1 min, T_R (minor): 29.9 min. ¹H NMR (CDCl₃, 500 MHz) δ = 7.88 (bs, 1H), 7.61 (d, *J* = 7.3 Hz, 2H), 7.58 (d, *J* = 7.9 Hz, 1H), 7.36-7.32 (m, 3H), 7.19 (t, *J* = 7.6 Hz, 2H), 7.09 (t, *J* = 7.6 Hz, 1H), 6.93 (d, *J* = 1.9 Hz, 1H), 6.57 (s, 1H), 4.47 (t, *J* = 6.6 Hz, 1H), 3.07-3.00 (m, 1H), 2.96-2.83 (m, 2H), 2.52-2.46 (m, 1H). ¹³C NMR (CDCl₃, 125 MHz) δ = 159.6, 158.0, 137.0, 132.1, 130.3, 128.8, 126.9, 126.9, 123.3, 122.3, 120.9, 120.7, 119.5 (2C), 111.4, 103.8, 37.7, 34.2, 25.0. HRMS (ESI): *m/z*: calculated for C₂₁H₁₆NO⁺: 298.1226 [M+H-H₂]⁺, found, 298.1227.

(R)-3-(2-phenyl-5,6,7,8-tetrahydro-4H-cyclohepta[b]furan-4-yl)-1H-indole (10ga)



Compound **10ga** was prepared according to the general procedure from **8g** (23.1 mg, 0.11 mmol, 1.1 equiv.), **9a** (11.7 mg, 0.1 mmol, 1.0 equiv.), **(S)-5** (0.17 mg, 0.0002 mmol, 0.2 mol %) and Ag₂CO₃ (0.1 mg, 0.0001 mmol, 0.1 mol %) in toluene (0.5 mL), yielding product **10ga** (13.5 mg, 0.04 mmol, 41 %) as a white solid. **[\alpha]**_D = +107 (*c* 0.59, CHCl₃). ee = 94 %, determined on a Chiralpak IA column (heptane:IPA = 95:05, 1 mL/min), retention times: T_R (minor): 14.8 min, T_R (major): 16.8 min.

10ga was alternatively obtained from the same protocol in the absence of Ag_2CO_3 in 55% yield and 95% ee.

¹H NMR (CDCl₃, 500 MHz) δ = 7.92 (bs, 1H), 7.61 (d, *J* = 7.9 Hz, 1H), 7.51 (d, *J* = 7.3 Hz, 2H), 7.36 (d, *J* = 8.2 Hz, 1H), 7.28 (t, *J* = 7.9 Hz, 2H), 7.19 (t, *J* = 7.6 Hz, 1H), 7.14 (t, *J* = 7.6 Hz, 1H), 7.10 (t, *J* = 7.6 Hz, 1H), 6.81 (d, *J* = 1.9 Hz, 1H), 6.25 (s, 1H), 4.27 (dd, *J*₁ = 7.6 Hz, *J*₂ = 3.2 Hz, 1H), 2.95 (t, *J* = 5.7 Hz, 2H), 2.33-2.28 (m, 1H), 2.09-2.04 (m, 1H), 1.83-1.76 (m, 3H),1.74-1.69 (m, 1H). ¹³C NMR (CDCl₃, 125 MHz) δ = 153.0, 150.0, 136.9, 131.4, 128.7, 126.8, 126.6, 126.2, 123.4, 122.6, 122.1, 120.0, 119.8, 119.4, 111.4, 109.1, 35.5, 34.6, 29.3, 27.6, 26.9. HRMS (ESI): *m/z*: calculated for C₂₃H₂₂NO⁺: 328.1696 [M+H]⁺, found, 328.1696.

(S)-3-methyl-2-(2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-1H-indole (14ah)



Compound **14ah** was prepared according to the general procedure from **8a** (21.6 mg, 0.11 mmol, 1.1 equiv.), **9g** (13.1 mg, 0.1 mmol, 1.0 equiv.), **(S)-5** (0.2 mg, 0.0002 mmol, 0.2 mol %) and Ag_2CO_3 (0.1 mg, 0.0001 mmol, 0.1 mol %) in toluene (0.5 mL), yielding product **14ah** (27.1 mg, 0.08 mmol, 83 %) as a pale yellow solid.

[α]_D = +83 (*c* 1.29, CHCl₃). ee = 93 %, determined on a Chiralpak IA column (heptane:IPA = 95:5, 1 mL/min), retention times: T_R (minor): 7.1 min, T_R (major): 10.3 min. ¹H NMR (CDCl₃, 500 MHz) δ = 7.63 (s, 1H), 7.58 (d, *J* = 7.6 Hz, 2H), 7.54-7.52 (m, 1H), 7.33 (t, *J* = 7.6 Hz, 2H), 7.22-7.19 (m, 2H), 7.12-7.07 (m, 2H), 6.35 (s, 1H), 4.25 (dd, J_1 = 7.3 Hz, J_2 = 5.8 Hz, 1H), 2.78 (t, *J* = 6.1 Hz, 2H), 2.33 (s, 3H), 2.17-2.11 (m, 1H), 2.05-1.98 (m, 1H), 1.93-1.85 (m, 1H), 1.83-1.76 (m, 1H). ¹³C NMR (CDCl₃, 125 MHz) δ = 152.6, 152.2, 137.2, 135.1, 131.2, 129.7, 129.0, 128.9, 128.7, 127.2, 123.5, 121.3, 120.1, 119.2, 118.3, 110.7, 107.0, 105.7, 31.8, 31.4, 23.4, 22.0, 8.7. HRMS (ESI): *m/z*: calculated for C₂₃H₂₀NO⁺: 326.1539 [M+H-H₂]⁺, found, 326.1541.

(S)-1,3-dimethyl-2-(2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-1H-indole (14ai)



Compound **14ai** was prepared according to the general procedure from **8a** (21.6 mg, 0.11 mmol, 1.1 equiv.), **9i** (14.5 mg, 0.1 mmol, 1.0 equiv.), **(S)-5** (0.2 mg, 0.0002 mmol, 0.2 mol %) and Ag_2CO_3 (0.1 mg, 0.0001 mmol, 0.1 mol %) in toluene (0.5 mL), yielding product **14ai** (20.5 mg, 0.07 mmol, 65 %) as a white solid.

[α]_D = +28 (*c* 0.94, CHCl₃). ee = 97 %, determined on a Chiralpak IC column (heptane:IPA = 95:5, 1 mL/min), retention times: T_R (major): 4.4 min, T_R (minor): 4.9 min. ¹H NMR (CDCl₃, 500 MHz) δ = 7.58 (d, *J* = 7.6 Hz, 2H), 7.55 (d, *J* = 7.9 Hz, 1H), 7.33 (t, *J* = 7.6 Hz, 2H), 7.26 (d, *J* = 8.2 Hz, 1H), 7.20 (td, *J*₁ = 7.3 Hz, *J*₂ = 3.1 Hz, 2H), 7.13 (t, *J* = 7.3 Hz, 1H), 6.32 (s, 1H), 4.37-4.35 (m, 1H), 3.58 (s, 3H), 2.84-2.81 (m, 2H), 2.23 (s, 3H), 2.20-2.11 (m, 2H), 2.00-1.87 (m, 2H). ¹³C NMR (CDCl₃, 125 MHz) δ = 152.5, 150.8, 137.4, 137.2, 131.3, 128.8, 128.7, 127.0, 123.5, 121.2, 118.9, 118.4, 108.8, 107.8, 105.6, 105.3, 32.0, 30.5, 23.4, 23.2, 9.2. HRMS (ESI): *m/z*: calculated for C₂₄H₂₄NO⁺: 342.1852 [M+H]⁺, found, 342.1853.

methyl (*S*)-2-(2-(2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-1H-indol-3-yl)acetate (14aj) and methyl (*S*)-2-(1-(2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-1H-indol-3-yl)acetate (15aj)



Compound **14aj** and **15aj** were prepared according to the general procedure from **8a** (23.1 mg, 0.11 mmol, 1.1 equiv.), **9j** (18.9 mg, 0.1 mmol, 1.0 equiv.), **(S)-5** (0.2 mg, 0.0002 mmol, 0.2 mol %) and Ag_2CO_3 (0.1 mg, 0.0001 mmol, 0.1 mol %) in toluene (0.5 mL), yielding product **14aj** (20 mg, 0.05 mmol, 52 %) as a white solid and **15ajk** (16.7 mg, 0.05 mmol, 46 %) as a white solid.

Data for 14aj

 $[\alpha]_{D}$ = +59 (*c* 1.08, CHCl₃). ee = 91 %, determined on a Chiralpak IC column (heptane:IPA = 98:2, 1 mL/min), retention times: T_R (minor): 31.8 min, T_R (major): 35.8 min. ¹H NMR (CDCl₃, 500 MHz) δ = 7.73 (bs, 1H), 7.54-7.50 (m, 3H), 7.26 (t, *J* = 7.9 Hz, 2H), 7.17-7.12 (m, 2H), 7.07-7.03 (m, 2H), 6.26 (s, 1H), 4.22 (dd, *J*₁ = 7.3 Hz, *J*₂ = 6.0 Hz, 1H), 3.73 (dd, *J*₁ = 22.8 Hz, *J*₂ = 15.4 Hz, 2H), 3.61 (s, 3H), 2.72 (t, *J* = 6.0 Hz, 2H), 2.16-2.11 (m, 1H), 1.99-1.96 (m, 1H), 1.88-1.80 (m, 1H), 1.78-1.71 (m, 1H). ¹³C NMR (CDCl₃, 125 MHz) δ = 172.6, 152.7, 152.3, 139.2, 135.1, 131.1, 128.9, 128.7, 128.7, 127.3, 123.5, 121.8, 119.9, 118.6, 110.9, 105.6, 104.5, 52.2, 31.9, 31.7, 30.4, 23.4, 22.1. HRMS (ESI): *m/z*: calculated for C₂₅H₂₄NO₃⁺: 386.1751 [M+H]⁺, found, 386.1751.

Data for 15aj

[α]_D = -4 (*c* 0.94, CHCl₃). ee = 95 %, determined on a Chiralpak IC column (heptane:IPA = 98:2, 1 mL/min), retention times: T_R (major): 23.1 min, T_R (minor): 25.9 min. ¹H NMR (CDCl₃, 500 MHz) δ = 7.63 (d, *J* = 7.9 Hz, 1H), 7.59 (d, *J* = 7.6 Hz, 2H), 7.39 (d, *J* = 8.5 Hz, 1H), 7.34 (t, *J* = 7.9 Hz, 2H), 7.23-7.20 (m, 2H), 7.14 (t, *J* = 7.6 Hz, 1H), 6.99 (s, 1H), 6.40 (s, 1H), 5.53 (d, *J* = 5.4 Hz, 1H), 3.72 (dd, *J*₁ = 18.6 Hz, *J*₂ = 16.1 Hz, 2H), 3.66 (s, 3H), 2.85 (dt, *J*₁ = 16.7 Hz, *J*₂ = 6.3 Hz, 1H), 2.74 (dt, *J*₁ = 16.7 Hz, *J*₂ = 6.3 Hz, 1H), 2.19-2.13 (m, 1H), 2.09-2.03 (m, 1H), 1.98-1.85 (m, 2H). ¹³C NMR (CDCl₃, 125 MHz) δ = 172.5, 153.2, 153.0, 135.9, 130.8, 128.7, 128.4, 127.2, 125.4, 123.5, 121.6, 119.4, 119.3, 118.5, 109.7, 106.8, 104.8, 77.3, 77.0, 76.8, 51.9, 50.0, 31.3, 30.6, 23.1, 20.3. HRMS (ESI): *m/z*: calculated for $C_{25}H_{24}NO_3^+$: 386.1751 [M+H]⁺, found, 386.1747.

(*S*)-3-isopropyl-2-(2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-1H-indole (14ak) and (*S*)-3-isopropyl-1-(2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-1H-indole (15ak)



Compound **14ak** and **15ak** were prepared according to the general procedure from **8a** (23.1 mg, 0.11 mmol, 1.1 equiv.), **9k** (15.9 mg, 0.1 mmol, 1.0 equiv.), **(S)-5** (0.2 mg, 0.0002 mmol, 0.2 mol %) and Ag_2CO_3 (0.1 mg, 0.0001 mmol, 0.1 mol %) in toluene (0.5 mL), yielding product **14ak** (7.4 mg, 0.06 mmol, 21 %) as a pale yellow solid and **15ak** (20.7 mg, 0.02 mmol, 59 %) as a pale yellow solid.

Data for 14ak

[α]_D = -14 (*c* 1.00, CHCl₃). ee = 49 %, determined on a Chiralpak IA column (heptane:IPA = 95:5, 1 mL/min), retention times: T_R (minor): 5.2 min, T_R (major): 6.9 min. ¹H NMR (CDCl₃, 500 MHz) δ = 7.66 (d, *J* = 7.0 Hz, 1H), 7.51 (d, *J* = 7.2 Hz, 2H), 7.26 (t, *J* = 7.7 Hz, 2H), 7.18-7.11 (m, 2H), 7.05-7.6.96 (m, 2H), 6.27 (s, 1H), 4.22 (dd, J_1 = 7.5 Hz, J_2 = 5.6 Hz, 1H), 3.22 (m, *J* = 7.1 Hz, 1H), 2.73-2.70 (m, 2H), 2.12-2.02 (m, 1H), 2.02-1.92 (m, 1H), 1.89-1.79 (m, 1H), 1.76-1.65 (m, 1H), 1.43 (t, *J* = 7.3 Hz, 6H). ¹³C NMR (CDCl₃, 125 MHz) δ = 152.6, 152.3, 135.9, 135.6, 131.1, 128.9, 127.4, 127.2, 123.5, 121.0, 120.3, 120.2, 118.9, 118.1, 111.0, 105.7, 32.3, 31.9, 26.1, 23.7, 23.6, 23.5, 22.1. HRMS (ESI): *m/z*: calculated for C₂₅H₂₆NO⁺: 356.2009 [M+H]⁺, found, 356.2009.

Data for 15ak

[α]_D = +16 (*c* 0.50, CHCl₃). ee = 92 %, determined on a Chiralpak IA column (heptane:IPA = 95:5, 1 mL/min), retention times: T_R (minor): 4.2 min, T_R (major): 4.6 min. ¹H NMR (CDCl₃, 500 MHz) δ = 7.71 (d, *J* = 7.9 Hz, 1H), 7.65 (d, *J* = 7.9 Hz, 2H), 7.42 (d, *J* = 8.2 Hz, 1H), 7.39 (t, *J* = 7.6 Hz, 2H), 7.28-7.22 (m, 2H), 7.15 (d, *J* = 7.6 Hz, 1H), 6.81 (s, 1H), 6.45 (s, 1H), 5.56 (t, *J* = 5.5, 1H), 3.21 (m, *J* = 6.7 Hz, 1H), 2.93-2.88 (m, 1H), 2.82-2.77 (m, 1H), 2.23-2.17 (m, 1H), 2.12-2.06 (m, 1H), 2.03-1.92 (m, 2H), 1.35 (dd, *J*₁ = 6.7 Hz, *J*₂ = 4.6 Hz, 6H). ¹³C NMR (CDCl₃, 125 MHz) δ = 153.2, 153.0, 136.5, 131.1, 128.9, 128.0, 127.3, 123.7, 122.6, 121.7, 121.4, 119.9, 119.2, 118.8, 109.8, 105.1, 50.1, 30.9, 25.8, 23.7, 23.6, 23.3, 20.7. HRMS (ESI): *m/z*: calculated for $C_{25}H_{26}NO^+$: 356.2009 [M+H]⁺, found, 356.2010.

benzyl (S)-(2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)carbamate (16a)



Compound **16a** was prepared according to a modified general procedure from **8a** (107.9 mg, 0.55 mmol, 1.1 equiv.), benzyl carbamate (75.6 mg, 0.5 mmol, 1.0 equiv.), **(S)-5** (8.4 mg, 0.01 mmol, 2 mol %) and Ag_2CO_3 (1.4 mg, 0.005 mmol, 1 mol %) in toluene (2.5 mL), yielding product **16a** (151.7 mg, 0.44 mmol, 88 %) as a white solid for which the spectroscopical data correspond to those reported in the literature.¹³

 $[\alpha]_D = -3$ (*c* 1.15, CHCl₃). ee = 94%, determined on a Chiralpak IB column (heptane:IPA = 97:3, 1 mL/min), retention times: T_R (minor): 17.7 min, T_R (major): 22.5 min. ¹H NMR (CDCl₃, 500 MHz) δ = 7.56 (d, *J* = 7.6 Hz, 2H), 7.33-7.29 (m, 7H), 7.18 (t, *J* = 7.3 Hz, 1H), 6.53 (s, 1H), 5.11 (s, 2H), 5.03 (d, *J* = 7.9 Hz, 1H), 4.75-4.74 (m, 1H), 2.63-2.54 (m, 2H), 2.00-1.96 (m, 1H), 1.88-1.80 (m, 2H), 1.69-1.66 (m, 1H). HRMS (ESI): *m/z*: calculated for C₂₂H₂₂NO₃⁺: 348.1594 [M+H]⁺, found, 348.1597.

(S)-4-methyl-N-(2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)benzenesulfonamide (16b)



Yield: 80 %, ee: 88 %.

Compound **16b** was prepared according to the general procedure from **8a** (107.9 mg, 0.55 mmol, 1.1 equiv.), tosylamide (85.6 mg, 0.5 mmol, 1.0 equiv.), **(S)-5** (0.8 mg, 0.001 mmol, 0.2 mol %) and Ag_2CO_3 (0.1 mg, 0.0005 mmol, 0.1 mol %) in toluene (2.5 mL), yielding product **16b** (146.4 mg, 0.40 mmol, 80 %) as a white solid for which the spectroscopical data correspond to those reported in the literature.¹³

When the reaction was performed with 0.2 mol% of catalyst (*S*)-5, the obtained ee was 94% but with a decrease of the yield to 17%.

16b was alternatively obtained from the same protocol in the absence of Ag_2CO_3 in 41% yield and 88% ee.

 $[\alpha]_{D} = -99 \ (c \ 1.14, \ CHCl_{3}). ee = 87\%, determined on a Chiralpak IC column (heptane:IPA = 90:10, 1 mL/min), retention times: T_R (major): 35.7 min, T_R (minor): 41.7 min. ¹H NMR (CDCl_{3}, 500 MHz) <math>\delta$ = 7.84 (d, $J = 8.2 \ Hz, 2H$), 7.46 (d, $J = 7.3 \ Hz, 2H$), 7.37 (d, $J = 8.2 \ Hz, 2H$), 7.33 (t, $J = 7.6 \ Hz, 2H$), 7.21 (t, $J = 7.3 \ Hz, 1H$), 5.86-5.85 (m, 1H), 4.59 (d, $J = 8.2 \ Hz, 1H$), 4.38-4.36 (m, 1H), 2.66-2.61 (m, 1H), 2.58-2.52 (1H), 2.48 (s, 3H),

1.90-1.73 (m, 4H). **HRMS (ESI)**: *m/z*: calculated for C₂₁H₂₀NO₃S⁻: 366.1169 [M-H]⁻, found, 366.1172.

(S)-N,2-diphenyl-4,5,6,7-tetrahydrobenzofuran-4-amine (16c)



Compound **16c** was prepared according to the general procedure from **8a** (21.6 mg, 0.11 mmol, 1.1 equiv.), aniline (0.009 mL, 0.1 mmol, 1.0 equiv.), **(S)-5** (8.4 mg, 0.01 mmol, 2 mol %) and Ag_2CO_3 (1.4 mg, 0.005 mmol, 1 mol %) in toluene (1 mL), yielding product **16c** (25.6 mg, 0.09 mmol, 89 %) as a white solid for which the spectroscopical data correspond to those reported in the literature.¹³

 $[\alpha]_D$ = +4 (*c* 0.95, CHCl₃). ee = 65%, determined on a Chiralpak IB column (heptane:IPA = 98:02, 1 mL/min), retention times: T_R (major): 10.5 min, T_R (minor): 14.0 min. ¹H NMR (CDCl₃, 500 MHz) δ = 7.59 (t, *J* = 7.3 Hz, 2H), 7.33 (t, *J* = 7.6 Hz, 2H), 7.24-7.19 (m, 3H), 6.74-6.68 (m, 3H), 6.58 (s, 1H), 4.56 (br, 1H), 3.79 (bs, 1H), 2.75-2.62 (m, 2H), 2.02-1.95 (m, 2H), 1.88-1.80 (m, 2H). HRMS (ESI): *m/z*: calculated for C₂₀H₁₈NO⁺: 288.1383 [M-H₂+H]⁺, found, 288.1393.

(S)-4-phenoxy-2-phenyl-4,5,6,7-tetrahydrobenzofuran (16d)



Compound **16d** was prepared according to the general procedure from **8a** (107.9 mg, 0.55 mmol, 1.1 equiv.), phenol (47.1 mg, 0.5 mmol, 1.0 equiv.), **(S)-5** (0.8 mg, 0.001 mmol, 0.2 mol %) and Ag_2CO_3 (0.1 mg, 0.0005 mmol, 0.1 mol %) in toluene (2.5 mL), yielding product **16d** (133.9 mg, 0.46 mmol, 93 %) as a white solid for which the spectroscopical data correspond to those reported in the literature.¹³

 $[\alpha]_{D} = -21$ (*c* 0.99, CHCl₃). ee = 90%, determined on a Chiralpak IB column (heptane:IPA = 98:02, 1 mL/min), retention times: T_R (major): 6.1 min, T_R (minor): 9.2 min. ¹H NMR (CDCl₃, 500 MHz) δ = 7.60 (d, *J* = 7.3 Hz, 2H), 7.35-7.30 (m, 4H), 7.21 (t, *J* = 7.3 Hz, 1H), 7.03 (d, *J* = 7.9 Hz, 2H), 6.98 (t, *J* = 7.3 Hz, 1H), 6.58 (s, 1H), 5.36 (t, *J* = 4.3 Hz, 1H), 2.80 (dt, *J*₁ = 16.8, *J*₂ = 5.2 Hz, 1H), 2.69-2.63 (m, 1H), 2.16-2.08 (m, 2H), 2.00-1.93 (m, 1H), 1.92-1.85 (m, 1H). HRMS (ESI): *m/z*: calculated for C₂₀H₁₇O₂⁺: 289.1223 [M-H₂+H]⁺, found, 289.1224.

(S)-2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-ol (16e),

(4S,4'S)-4,4'-oxybis(2-phenyl-4,5,6,7-tetrahydrobenzofuran) (16eb) and

(S)-2-phenyl-4-(((R)-2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)oxy)-4,5,6,7-tetrahydrobenzofuran (16ec)



Compound **16e** was prepared according to the general procedure from **8a** (98.1 mg, 0.5 mmol, 1.0 equiv.), water (0.03 mL, 1.5 mmol, 3.0 equiv.), **(S)-5** (0.8 mg, 0.001 mmol, 0.2 mol %) and Ag_2CO_3 (0.1 mg, 0.0005 mmol, 0.1 mol %) in toluene (2.5 mL), yielding products **16ea** (34.3 mg, 0.16 mmol, 32 %), **16eb** (50.9 mg, 0.25 mmol, 50 %) and **16ec** (18.1 mg, 0.09 mmol, 18 %) as white solids.

Data for 16ea: 13

 $[\alpha]_D$ = +12 (*c* 1.44, CHCl₃). ee = 97%, determined on a Chiralpak IB column (heptane:IPA = 98:2, 1 mL/min), retention times: T_R (major): 28.3 min, T_R (minor): 34.5 min. ¹H NMR (CDCl₃, 500 MHz) δ = 7.62 (d, *J* = 7.3 Hz, 2H), 7.35 (t, *J* = 7.6 Hz, 2H), 7.22 (t, *J* = 7.6 Hz, 1H), 6.66 (s, 1H), 4.77-4.75 (m, 1H), 2.75-2.69 (m, 1H), 2.64-2.58 (m, 1H), 2.08-2.00 (m, 1H), 1.98-1.92 (m, 1H), 1.89-1.78 (m, 2H), 1.62 (s, 1H). HRMS (ESI): *m/z*: calculated for C₁₄H₁₃O₂⁺: 213.0910 [M-H₂+H]⁺, found, 213.0912.

Data for 16eb:

[α]_D = +75 (*c* 0.95, CHCl₃). ¹H NMR (CDCl₃, 500 MHz) δ = 7.61 (d, *J* = 7.9 Hz, 4H), 7.34 (t, *J* = 7.9 Hz, 4H), 7.20 (t, *J* = 7.3 Hz, 2H), 6.61 (s, 2H), 4.62 (t, *J* = 3.8 Hz, 2H), 2.74 (dt, *J*₁ = 16.4 Hz, *J*₂ = 5.0 Hz, 2H), 2.64-2.58 (m, 2H), 2.16-2.11 (m, 2H), 2.03-1.99 (m, 2H), 1.92-1.87 (m, 4H). ¹³C NMR (CDCl₃, 125 MHz) δ = 153.0, 131.4, 128.9, 128.8, 127.1, 123.7, 120.9, 105.3, 69.2, 29.8, 23.5, 19.2. HRMS (ESI): *m/z*: calculated for $C_{28}H_{27}O_3^+$: 411.1955 [M+H]⁺, found, 411.1956.

Data for 16ec:

¹H NMR (CDCl₃, 500 MHz) δ = 7.62 (d, *J* = 7.9 Hz, 4H), 7.34 (t, *J* = 7.6 Hz, 4H), 7.20 (t, *J* = 7.3 Hz, 2H), 6.61 (s, 2H), 4.70 (t, *J* = 4.1 Hz, 2H), 2.75 (dt, *J*₁ = 16.4 Hz, *J*₂ = 5.3 Hz, 2H), 2.66-2.60 (m, 2H), 2.16-2.10 (m, 2H), 1.96-1.93 (m, 4H), 1.88-1.84 (m, 2H). ¹³C NMR (CDCl₃, 125 MHz) δ = 152.9, 131.4, 128.8, 127.1, 123.8, 123.7, 121.1, 105.3, 69.3, 30.2, 23.5, 19.5. HRMS (ESI): *m/z*: calculated for C₂₈H₂₇O₃⁺: 411.1955 [M+H]⁺, found, 411.1953.

(S)-3-((2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)oxy)cyclohex-2-en-1-one (16f)



Na

Yield: 77 %, ee: 89 %.

Compound **16f** was prepared according to the general procedure from **8a** (21.6 mg, 0.11 mmol, 1.1 equiv.), **9b** (11.2 mg, 0.1 mmol, 1.0 equiv.), **(S)-5** (0.2 mg, 0.0002 mmol, 0.2 mol %) and Ag_2CO_3 (0.1 mg, 0.0001 mmol, 0.1 mol %) in toluene (0.5 mL), yielding product **16f** (23.6 mg, 0.77 mmol, 77 %) as a white solid for which the spectroscopical data correspond to those reported in the literature.¹³

 $[\alpha]_{D} = -150 \ (c \ 0.92, \ CHCl_{3}). \ ee: 89 \%, \ determined \ on a Chiralpak IA column (heptane:IPA = 98:02, 1 mL/min), retention times: T_R (major): 22.8 min, T_R (minor): 27.1 min. ¹H NMR (CDCl₃, 300 MHz) <math>\delta$ = 7.54 (d, $J = 7.3 \ Hz, 2H$), 7.28 (t, $J = 7.5 \ Hz, 2H$), 7.16 (t, $J = 7.7 \ Hz, 1H$), 6.53 (s, 1H), 5.54 (s, 1H), 5.19 (t, $J = 3.6 \ Hz, 1H$), 2.72 (dt, $J_1 = 16.8 \ Hz, J_2 = 4.7 \ Hz, 1H$), 2.63-2.53 (m, 1H), 2.37-2.29 (m, 4H), 2.05-1.79 (m, 6H). HRMS (ESI): m/z: calcd for C₄₀H₄₀NaO₆⁺ 639.2723 [2M+Na]⁺, found, 639.2717.

6. X-ray Crystallography

X-ray diffraction data were measured for 10aa and (S)-5 using a RIGAKU diffractometer constituted by a MM007 HF rotating-anode generator, delivering copper radiation through Osmic CMF confocal optics, and a Rapid II curved Image Plate detector. Fs_process¹⁴ software under the CrystalClear 2.0¹⁵ suite was used to integrate and scale the data, applying multi-scan REQAB⁶ for the absorption correction. Regarding SI-1, the data collection was carried out with a RIGAKU XtaLabPro diffractometer equipped with a Mo microfocus sealed tube generator coupled to a double-bounce confocal Max-Flux® multilayer optic and a HPAD PILATUS3R 200K detector. CrysAlisPro 1.171.39.46¹⁶ was employed for the data processing, with SCALE3 ABSPACK scaling algorithm implemented for the empirical absorption correction using spherical harmonics. The structures were solved either by dual-space direct methods (SHELXD program),¹⁷ (regarding the two first ones) or by intrinsic phasing methods (SHELXT program),¹⁸ and all were refined by full-matrix least-squares methods on F² using SHELX-L.¹⁹ All non-hydrogen atoms of the molecules of interest improved by anisotropic refinement. Most of the H atoms were identified in difference maps. Methyl H atoms of the solvent isopropanol molecule present in the (S)-5 structure were idealized and included as rigid groups allowed to rotate but not tip, and refined with U_{iso} set to $1.5U_{eq}(C)$ of the parent carbon atom. All other H atoms bound to carbon atoms were positioned geometrically and refined with $U_{\rm iso}$ set to $1.2U_{\rm eq}(C)$ of the parent carbon atom. The position of the hydrogen atom in the NH group in **10aa** was refined freely with U_{iso} set to $1.2U_{eq}(N)$. The NH group is pointing perpendicularly toward the six-membered moiety of the indole at x+0.5, 0.5-y, 1-z at a 2.60 Å distance. The two hydroxy H atoms in (S)-5 were allowed to change the torsion angle (instruction AFIX 147) and their displacement parameters were related with U_{iso} set to 1.5 $U_{eq}(O)$. A BUMP instruction was nevertheless applied to prevent steric clashes between them, the hydroxyl group of the solvent molecule bridging two phosphate moieties at x, y, z and x-0.5, 1.5-y, 1-z respectively, via O-H...O H-bonds generating the chain motifs $C_{2}^{2}(6)$.²⁰ The anisotropic displacement parameters of atoms in a phenyl group were restrained using the RIGU²¹ instruction. Crystal data, data collection and structure refinement details are summarized in Table S1. The three structures have in common to belong to the same space group P $2_1 2_1 2_1$ and only the third one has more than one molecule in the asymmetric unit (ie 2). The absolute structures for (S)-5 and SI-1 were straightforwardly confirmed by dispersion effects, mainly provided by the Au M (at the Cu source excitation) and L (with the Mo source) far-absorption edges (> 5e-): both compounds synthesized from pure aS binol conserved that axial chirality. Moreover the tetracoordinate phosphorus stereogenic centre in SI-1 is (*R_P*). Absence of strong anomalous scatterers in 10aa could have hampered its absolute structure determination on C1(R) but highly redundant data quality coupled with intense microfocused copper

¹⁴ Rigaku - Higashi T. FS Process, Rigaku Corporation, **1998**, Tokyo, Japan.

¹⁵ Rigaku. CrystalClear-SM Expert 2.0 r4 Rigaku Corporation, **2009**, Tokyo, Japan.

¹⁶ Rigaku OD CrysAlis PRO. Rigaku Oxford Diffraction, Yarnton, Oxfordshire, **2015**, England.

¹⁷ Sheldrick, G. M. Acta Crystallogr., **2008**, A64, 112-122

¹⁸ Drick, G. M. Acta Crystallogr., **2015**, C71, 3-8.

¹⁹ Drick, G. M. Acta Crystallogr., **2015**, A71, 3-8.

²⁰ Bernstein, J., Davis, R. E., Shimoni, L. & Chang, N. L. Angew. Chem. Int. Ed. Engl. **1995**, 34, 1555-1573.

²¹ Thorn, A., Dittrich, B. & Sheldrick, G. M. Acta Crystallogr., **2012**, A68, 448-451.

radiation led to significant Flack²² parameter estimate in favour of that assignment. This was corroborated later on by Bayesian-type analysis²³ upon 100 % Bijvoet pairs of reflections, as implemented within the PLATON program²⁴ (see **Table S1**).



Figure S1. X-ray Molecular Structure of 10aa



Figure S2. X-ray Molecular Structure of (S)-5

²² Flack, H.D. *Acta Crystallogr.*, **1983**, A39, 876-881.

²³ Hooft, R.W.W., Straver, L.H., Spek, A.L. J. Appl. Cryst., **2008**, 41, 96-103.

²⁴ Spek, A. L. *Acta Crystallogr.*, **2009**, D65, 148-155.



Figure S3. X-ray Molecular Structure of SI-1

Table S1 Crystal data, data collection and structure refinement details for the 3 compounds.

| Compound | | 10aa | (<i>S</i>)-5 | SI-1 |
|------------------------------------|----------------|--|---|--|
| Empirical formula | | $C_{22}H_{19}NO$ | C ₃₈ H ₂₆ AuClO ₄ P ₂ , <i>C₃H₈O</i> | $C_{38}H_{25}AuCl_2O_3P_2$ |
| Formula weight | | 313.38 | 901.04 | 859.39 |
| Temperature (K) | | 293(2) | 293(2) | 293(2) |
| Wavelength (Å) | | 1.54187 | 1.54187 | 0.71073 |
| Crystal system, | | Orthorhombic, | Orthorhombic, | Orthorhombic, |
| space group | | P 2 ₁ 2 ₁ 2 ₁ | P 2 ₁ 2 ₁ 2 ₁ | P 2 ₁ 2 ₁ 2 ₁ |
| Unit cell dimensions | a (Å) | 6.6896(3) | 10.8015(2) | 11.26267(18) |
| | b (Å) | 8.6995(3) | 17.6790(3) | 19.0781(4) |
| | c (Å) | 28.863(2) | 19.6851(14) | 31.7278(6) |
| | α (°) | 90 | 90 | 90 |
| | β (°) | 90 | 90 | 90 |
| | γ (°) | 90 | 90 | 90 |
| Volume (ų) | | 1679.72(15) | 3759.1(3) | 6817.4(2) |
| Ζ, | | 4, | 4, | 8, |
| Calculated density (mg/m | ³) | 1.239 | 1.592 | 1.675 |
| Absorption coefficient (m | m⁻¹) | 0.588 | 9.165 | 4.603 |
| F(000) | | 664 | 1784 | 3360 |
| Crystal size (mm) | | 0.42 x 0.34 x 0.29 | $0.35 \times 0.26 \times 0.22$ | $0.30\times0.18\times0.10$ |
| heta range for data collection (°) | | 3.062 to 68.230 | 4.492 to 68.235 | 3.618 to 29.083 |
| Limiting indices | | -7 ≤ h ≤ 7, | -12 ≤ h ≤ 12, | -11 ≤ h ≤ 15, |
| | | -10 ≤ k ≤ 7, | -21 ≤ k ≤ 18, | -21 ≤ k ≤ 25, |
| | | -34 ≤ l ≤ 34 | -20 ≤ l ≤ 23 | -35 ≤ l ≤ 42 |
| Reflections collected / un | ique | 21364 / 3065 | 32647 / 6835 | 78149 / 15931 |

| [R(int) | | 0.0303 | 0.0462 | 0.0614 |
|--|---------------------------------|-----------------|----------------------|----------------------------|
| Completeness to $	heta$ _{full} (%) | | 99.7 | 99.0 | 99.5 |
| Absorption correction | Semi-empirical from equivalents | | | valents |
| Max. and Min. transmission | | 1.000 and 0.815 | 1.000 and 0.605 | 1.000 and 0.264 |
| Refinement method | | Full-i | matrix least-squares | s on <i>F</i> ² |
| Data / restraints / parameters | | 3063 / 0/ 221 | 6802 / 39 / 456 | 15910 / 0 / 829 |
| Goodness-of-fit on <i>F</i> ² | | 1.074 | 1.079 | 1.045 |
| Final R indices | R1 | 0.0297 | 0.0361 | 0.0437 |
| [<i>l</i> >2 <i>o</i> (<i>l</i>)] | wR2 | 0.0746 | 0.0837 | 0.0874 |
| R indices | R1 | 0.0326 | 0.0386 | 0.0661 |
| (all data) | wR2 | 0.0788 | 0.0867 | 0.0927 |
| Absolute structure parameter | | | | |
| Flack x ¹⁴ | | 0.03(6) | -0.023(3) | -0.005(3) |
| Parsons z ²⁵ | | 0.00(7) | -0.023(4) | -0.004(3) |
| Hooft y ¹⁵ | | 0.02(5) | -0.027(4) | -0.011(4) |
| P2 (true) | | 100% | 100% | 100% |
| P3 (true) | | 100% | 100% | 100% |
| Extinction coefficient | | 0.0017(6) | - | - |
| Largest diff. peak and hole (e.Å ⁻³) | | 0.104 and | 1 607 and -0 460 | 1 700 and -1 761 |
| | | -0.123 | 1.007 and -0.400 | 1.700 and -1.701 |

CCDC 1884441-1884443 (compounds **10aa**, **(S)-5**, and **SI-1** respectively) contain the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via <u>www.ccdc.cam.ac.uk/data_request/cif</u>

²⁵ Parsons, Flack and Wagner, *Acta Crystallogr.*, **2013**, B69 249-259.

7. HPLC traces



HPLC Analysis for 10aa: HPLC Chiralpak IA column [heptane:IPA = 95:05, 1 mL/min, λ = 277 nm, retention times: T_R (minor): 19.7 min, T_R (major): 25.6 min].



| | Channel Description | RT | Area | % Area |
|---|---------------------------------|--------|----------|--------|
| 1 | PDA 200.0 to 400.0 nm at 2.4 nm | 18.642 | 14502314 | 49.78 |
| 2 | PDA 200.0 to 400.0 nm at 2.4 nm | 23.308 | 14628255 | 50.22 |



| | Channel Description | RT | Area | % Area |
|---|---------------------------------|--------|----------|--------|
| 1 | PDA 200.0 to 400.0 nm at 2.4 nm | 19.728 | 261081 | 1.93 |
| 2 | PDA 200.0 to 400.0 nm at 2.4 nm | 25.607 | 13248494 | 98.07 |


HPLC Analysis for 10ab: HPLC Chiralpak IA column [heptane:IPA = 95:05, 1 mL/min, λ = 277 nm, retention times: T_R (minor): 29.2 min, T_R (major): 41.4 min].



| | Channel Description | RT | Area | % Area |
|---|---------------------------------|--------|----------|--------|
| 1 | PDA 200.0 to 400.0 nm at 2.4 nm | 29.169 | 20533331 | 49.83 |
| 2 | PDA 200.0 to 400.0 nm at 2.4 nm | 41.691 | 20670930 | 50.17 |



| | Channel Description | RT | Area | % Area |
|---|---------------------------------|--------|----------|--------|
| 1 | PDA 200.0 to 400.0 nm at 2.4 nm | 29.190 | 407299 | 1.51 |
| 2 | PDA 200.0 to 400.0 nm at 2.4 nm | 41.388 | 26563035 | 98.49 |



HPLC Analysis for 10ac: HPLC Chiralpak IA column [heptane:IPA = 95:05, 1 mL/min, λ = 277 nm, retention times: T_R (minor): 19.4 min, T_R (major): 26.7 min].



| | Channel Description | RT | Area | % Area |
|---|---------------------------------|--------|----------|--------|
| 1 | PDA 200.0 to 400.0 nm at 2.4 nm | 18.796 | 11907602 | 49.92 |
| 2 | PDA 200.0 to 400.0 nm at 2.4 nm | 25.443 | 11944609 | 50.08 |



| | Channel Description | RT | Area | % Area |
|---|---------------------------------|--------|----------|--------|
| 1 | PDA 200.0 to 400.0 nm at 2.4 nm | 19.356 | 280233 | 1.56 |
| 2 | PDA 200.0 to 400.0 nm at 2.4 nm | 26.659 | 17640550 | 98.44 |



HPLC Analysis for 10ad: HPLC Chiralpak IA column [heptane:IPA = 95:05, 1 mL/min, λ = 277 nm, retention times: T_R (minor): 19.5 min, T_R (major): 22.4 min].





| | Channel Description | RT | Area | % Area |
|---|---------------------------------|--------|----------|--------|
| 1 | PDA 200.0 to 400.0 nm at 2.4 nm | 19.458 | 497201 | 2.02 |
| 2 | PDA 200.0 to 400.0 nm at 2.4 nm | 22.433 | 24129004 | 97.98 |



HPLC Analysis for 10ae: HPLC Chiralpak AD-H column [heptane:IPA = 90:10, 1 mL/min, λ = 277 nm, retention times: T_R (minor): 4.3 min, T_R (major): 5.3 min].



| | Channel Description | RT | Area | % Area |
|---|---------------------------------|-------|---------|--------|
| 1 | PDA 200.0 to 400.0 nm at 2.4 nm | 4.323 | 3967340 | 50.30 |
| 2 | PDA 200.0 to 400.0 nm at 2.4 nm | 5.379 | 3920104 | 49.70 |



| | Channel Description | RT | Area | % Area |
|---|---------------------------------|-------|----------|--------|
| 1 | PDA 200.0 to 400.0 nm at 2.4 nm | 4.299 | 1217284 | 8.92 |
| 2 | PDA 200.0 to 400.0 nm at 2.4 nm | 5.339 | 12435400 | 91.08 |



HPLC Analysis for 10af: HPLC Chiralpak IC column [heptane:IPA = 95:05, 1 mL/min, λ = 277 nm, retention times: T_R (minor): 4.7 min, T_R (major): 5.1 min].



| | Channel Description | RT | Area | % Area |
|---|---------------------------------|-------|----------|--------|
| 1 | PDA 200.0 to 400.0 nm at 2.4 nm | 4.718 | 18557092 | 49.53 |
| 2 | PDA 200.0 to 400.0 nm at 2.4 nm | 5.134 | 18910286 | 50.47 |



| | Channel Description | RT | Area | % Area |
|---|---------------------------------|-------|----------|--------|
| 1 | PDA 200.0 to 400.0 nm at 2.4 nm | 4.728 | 305767 | 2.89 |
| 2 | PDA 200.0 to 400.0 nm at 2.4 nm | 5.127 | 10285879 | 97.11 |



HPLC Analysis for 10ag: HPLC Chiralpak IA column [heptane:IPA = 95:05, 1 mL/min, λ = 277 nm, retention times: T_R (minor): 6.5 min, T_R (major): 11.3 min].





HPLC Analysis for 10ba: HPLC Chiralpak IC column [heptane:IPA = 95:05, 1 mL/min, λ = 277 nm, retention times: T_R (minor): 9.5 min, T_R (major): 10.5 min].





| | Channel Description | RT | Area | % Area |
|---|---------------------------------|--------|----------|--------|
| 1 | PDA 200.0 to 400.0 nm at 2.4 nm | 9.450 | 859446 | 4.31 |
| 2 | PDA 200.0 to 400.0 nm at 2.4 nm | 10.476 | 19073662 | 95.69 |



HPLC Analysis for 10ca: HPLC Chiralpak IC column [heptane:IPA = 95:05, 1 mL/min, λ = 277 nm, retention times: T_R (minor): 6.3 min, T_R (major): 7.2 min].







HPLC Analysis for 10da: HPLC Chiralpak IA column [heptane:IPA = 90:10, 1 mL/min, λ = 277 nm, retention times: T_R (minor): 12.1 min, T_R (major): 23.7 min].





| | Channel Description | RT | Area | % Area |
|---|---------------------------------|--------|----------|--------|
| 1 | PDA 200.0 to 400.0 nm at 2.4 nm | 12.110 | 3174489 | 7.83 |
| 2 | PDA 200.0 to 400.0 nm at 2.4 nm | 23.673 | 37371650 | 92.17 |



HPLC Analysis for 10ea: HPLC Chiralpak IA column [heptane:IPA = 95:05, 1 mL/min, λ = 277 nm, retention times: T_R (minor): 8.7 min, T_R (major): 10.5 min].



| | Channel Description | RT | Area | % Area |
|---|---------------------------------|--------|----------|--------|
| 1 | PDA 200.0 to 400.0 nm at 2.4 nm | 9.644 | 35915017 | 49.72 |
| 2 | PDA 200.0 to 400.0 nm at 2.4 nm | 11.937 | 36319260 | 50.28 |



| | Channel Description | RT | Area | % Area |
|---|---------------------------------|--------|----------|--------|
| 1 | PDA 200.0 to 400.0 nm at 2.4 nm | 8.712 | 1275487 | 6.34 |
| 2 | PDA 200.0 to 400.0 nm at 2.4 nm | 10.543 | 18829441 | 93.66 |



HPLC Analysis for 10fa: HPLC Chiralpak IA column [heptane:IPA = 95:05, 1 mL/min, λ = 277 nm, retention times: T_R (major): 26.1 min, T_R (minor): 29.9 min].





HPLC Analysis for 10ga: HPLC Chiralpak IA column [heptane:IPA = 95:05, 1 mL/min, λ = 277 nm, retention times: T_R (minor): 14.8 min, T_R (major): 16.8 min].





| | Channel Description | RT | Area | % Area |
|---|---------------------------------|--------|----------|--------|
| 1 | PDA 200.0 to 400.0 nm at 2.4 nm | 14.823 | 794521 | 3.18 |
| 2 | PDA 200.0 to 400.0 nm at 2.4 nm | 16.760 | 24213709 | 96.82 |



HPLC Analysis for 14ah: HPLC Chiralpak IA column [heptane:IPA = 95:05, 1 mL/min, λ = 277 nm, retention times: T_R (minor): 7.1 min, T_R (major): 10.3 min].





| | • | | | |
|---|---------------------------------|--------|---------------------|-------|
| 1 | PDA 200.0 to 400.0 nm at 2.4 nm | 7.055 | <mark>535381</mark> | 3.56 |
| 2 | PDA 200.0 to 400.0 nm at 2.4 nm | 10.291 | 14502158 | 96.44 |
| | • | | | |



HPLC Analysis for 14ai: HPLC Chiralpak IC column [heptane:IPA = 95:05, 1 mL/min, λ = 277 nm, retention times: T_R (major): 4.4 min, T_R (minor): 4.9 min].





| | Channel Description | RT | Area | % Area |
|---|---------------------------------|-------|----------|--------|
| 1 | PDA 200.0 to 400.0 nm at 2.4 nm | 4.441 | 23702749 | 98.39 |
| 2 | PDA 200.0 to 400.0 nm at 2.4 nm | 4.872 | 387660 | 1.61 |



HPLC Analysis for 14aj: HPLC Chiralpak IC column [heptane:IPA = 98:02, 1 mL/min, λ = 277 nm, retention times: T_R (minor): 31.8 min, T_R (major): 35.8 min].







HPLC Analysis for 15aj: HPLC Chiralpak IC column [heptane:IPA = 98:02, 1 mL/min, λ = 277 nm, retention times: T_R (major): 23.1 min, T_R (minor): 25.9 min].







HPLC Analysis for 14ak: HPLC Chiralpak IA column [heptane:IPA = 95:05, 1 mL/min, λ = 277 nm, retention times: T_R (minor): 5.2 min, T_R (major): 6.9 min].







HPLC Analysis for 15ak: HPLC Chiralpak IA column [heptane:IPA = 95:05, 1 mL/min, λ = 277 nm, retention times: T_R (minor): 4.2 min, T_R (major): 4.6 min].







HPLC Analysis for 16a: HPLC Chiralpak IB column [heptane:IPA = 97:03, 1 mL/min, λ = 277 nm, retention times: T_R (minor): 17.7 min, T_R (major): 22.5 min].



| | Channel Description | RT | Area | % Area |
|---|---------------------------------|--------|----------|--------|
| 1 | PDA 200.0 to 400.0 nm at 2.4 nm | 18.141 | 11199041 | 49.99 |
| 2 | PDA 200.0 to 400.0 nm at 2.4 nm | 22.555 | 11201882 | 50.01 |



| | Channel Description | RT | Area | % Area |
|---|---------------------------------|--------|----------|--------|
| 1 | PDA 200.0 to 400.0 nm at 2.4 nm | 17.749 | 486446 | 3.02 |
| 2 | PDA 200.0 to 400.0 nm at 2.4 nm | 22.495 | 15613303 | 96.98 |



HPLC Analysis for 16b: HPLC Chiralpak IC column [heptane:IPA = 90:10, 1 mL/min, λ = 277 nm, retention times: T_R (major): 35.7 min, T_R (minor): 41.7 min].



| | Channel Description | RT | Area | % Area |
|---|---------------------------------|--------|---------|--------|
| 1 | PDA 200.0 to 400.0 nm at 2.4 nm | 34.719 | 9948385 | 50.17 |
| 2 | PDA 200.0 to 400.0 nm at 2.4 nm | 40.249 | 9882336 | 49.83 |



| | Channel Description | RT | Area | % Area |
|---|---------------------------------|--------|----------|--------|
| 1 | PDA 200.0 to 400.0 nm at 2.4 nm | 35.650 | 57606806 | 93.50 |
| 2 | PDA 200.0 to 400.0 nm at 2.4 nm | 41.699 | 4006807 | 6.50 |



HPLC Analysis for 16c: HPLC Chiralpak IB column [heptane:IPA = 98:02, 1 mL/min, λ = 277 nm, retention times: T_R (major): 10.5 min, T_R (minor): 14.0 min].



| | Channel Description | RT | Area | % Area |
|---|---------------------------------|--------|----------|--------|
| 1 | PDA 200.0 to 400.0 nm at 2.4 nm | 9.042 | 27706662 | 49.68 |
| 2 | PDA 200.0 to 400.0 nm at 2.4 nm | 11.564 | 28064942 | 50.32 |



| | Channel Description | RT | Area | % Area |
|---|---------------------------------|--------|----------|--------|
| 1 | PDA 200.0 to 400.0 nm at 2.4 nm | 10.476 | 23784879 | 82.29 |
| 2 | PDA 200.0 to 400.0 nm at 2.4 nm | 13.995 | 5120127 | 17.71 |



HPLC Analysis for 16d: HPLC Chiralpak IB column [heptane:IPA = 98:02, 1 mL/min, λ = 277 nm, retention times: T_R (major): 6.1 min, T_R (minor): 9.2 min].





| | Channel Description | RT | Area | % Area |
|---|---------------------------------|-------|----------|--------|
| 1 | PDA 210.0 to 400.0 nm at 1.2 nm | 6.116 | 17023277 | 94.90 |
| 2 | PDA 210.0 to 400.0 nm at 1.2 nm | 9.228 | 914783 | 5.10 |

о + ОН 16е

HPLC Analysis for 16e: HPLC Chiralpak IB column [heptane:IPA = 98:02, 1 mL/min, λ = 277 nm, retention times: T_R (major): 28.3 min, T_R (minor): 34.5 min].



| | Channel Description | RT | Area | % Area |
|---|---------------------------------|--------|---------|--------|
| 1 | PDA 200.0 to 400.0 nm at 2.4 nm | 26.936 | 5708912 | 50.56 |
| 2 | PDA 200.0 to 400.0 nm at 2.4 nm | 32.667 | 5583065 | 49.44 |





HPLC Analysis for 16f: HPLC Chiralpak IA column [heptane:IPA = 95:05, 1 mL/min, λ = 277 nm, retention times: T_R (minor): 22.8 min, T_R (major): 27.1 min].





| | Channel Description | RT | Area | % Area |
|---|---------------------------------|--------|----------|--------|
| 1 | PDA 200.0 to 400.0 nm at 2.4 nm | 22.796 | 61326122 | 94.50 |
| 2 | PDA 200.0 to 400.0 nm at 2.4 nm | 27.129 | 3572509 | 5.50 |

8. Copies of NMR Spectra



¹³C NMR (CDCl₃, 75 MHz) spectrum of (S)-2,2'-bis(methoxymethoxy)-1,1'-binaphthalene



¹H NMR (CDCl₃, 300 MHz) spectrum of (S)-2- (2,2'-*bis*(methoxymethoxy)- [1,1'-binaphthalen]-3-yl)- 4,4,5,5-tetramethyl-1,3,2-dioxaborolane [(S)-1]



¹³C NMR (CDCl₃, 75 MHz) spectrum of (S)-2- (2,2'-*bis*(methoxymethoxy)- [1,1'-binaphthalen]-3-yl)- 4,4,5,5-tetramethyl-1,3,2-dioxaborolane [(S)-1]



¹H NMR (CDCl₃, 500 MHz) spectrum of (*S*)-(2-(2,2'-dihydroxy-[1,1'-binaphthalen]-3-yl)phenyl)diphenylphosphine oxide [(*S*)-2]



¹³C NMR (CDCl₃, **125** MHz) spectrum of (*S*)-(2-(2,2'-dihydroxy-[1,1'-binaphthalen]-3-yl)phenyl)diphenylphosphine oxide [(*S*)-2]



³¹P NMR (CDCl₃, 200 MHz) spectrum of (*S*)-(2-(2,2'-dihydroxy-[1,1'-binaphthalen]-3-yl)phenyl)diphenylphosphine oxide [(*S*)-2]



¹H NMR (CDCl₃, 500 MHz) spectrum of (S)-3-(2-(diphenylphosphaneyl)phenyl)-[1,1'-binaphthalene]-2,2'-diol [(S)-3]



¹³C NMR(CDCl₃, 125 MHz) spectrum of (S)-3-(2-(diphenylphosphaneyl)phenyl)-[1,1'-binaphthalene]-2,2'-diol [(S)-3]



³¹P NMR (CDCl₃, 120 MHz) spectrum of (S)-3-(2-(diphenylphosphaneyl)phenyl)-[1,1'-binaphthalene]-2,2'-diol [(S)-3]



¹H NMR (CDCl₃, 500 MHz) spectrum of (S)-(2-(2,2'-dihydroxy-[1,1'-binaphthalen]-3-yl)phenyl)diphenylphosphine gold(I) chloride [(S)-4]



¹³C NMR(CDCl₃, 125 MHz) spectrum of (S)-(2-(2,2'-dihydroxy-[1,1'-binaphthalen]-3-yl)phenyl)diphenylphosphine gold(I) chloride [(S)-4]



³¹P NMR (CDCl₃, 200 MHz) spectrum of (*S*)-(2-(2,2'-dihydroxy-[1,1'-binaphthalen]-3-yl)phenyl)diphenylphosphine gold(I) chloride [(*S*)-4]



¹H NMR (DMSO, 343K, 500 MHz) spectrum of (*S*)-(2-(2,2'-diyl hydrogen phosphate-[1,1'-binaphthalen]-3-yl)phenyl) diphenylphosphine gold(I) chloride [(*S*)-5]



¹³C NMR (DMSO, 343K, 125 MHz) spectrum of (S)-(2-(2,2'-diyl hydrogen phosphate-[1,1'-binaphthalen]-3-yl)phenyl) diphenylphosphine gold(I) chloride [(S)-5]



³¹P NMR (DMSO, 343K, 200 MHz) spectrum of (*S*)-(2-(2,2'-diyl hydrogen phosphate-[1,1'-binaphthalen]-3-yl)phenyl) diphenylphosphine gold(I) chloride [(*S*)-5]



³¹P NMR (DMSO, 383K, 200 MHz) spectrum of (*S*)-(2-(2,2'-diyl hydrogen phosphate-[1,1'-binaphthalen]-3-yl)phenyl) diphenylphosphine gold(I) chloride [(*S*)-5]



¹H NMR (Pyridine, 500 MHz) spectrum of (S)-(2-(2,2'-diyl hydrogen phosphate-[1,1'-binaphthalen]-3-yl)phenyl) diphenylphosphine gold(I) chloride [(S)-5]



¹³C NMR (Pyridine, 125 MHz) spectrum of (S)-(2-(2,2'-diyl hydrogen phosphate-[1,1'-binaphthalen]-3-yl)phenyl) diphenylphosphine gold(I) chloride [(S)-5]



³¹P NMR (Pyridine, 200 MHz) spectrum of (*S*)-(2-(2,2'-diyl hydrogen phosphate-[1,1'-binaphthalen]-3-yl)phenyl) diphenylphosphine gold(I) chloride [(*S*)-5]



¹H NMR (CDCl₃, 500 MHz) spectrum of (S)-(2-(2,2'-diyl hydrogen phosphate-[1,1'-binaphthalen]-3-yl)phenyl) diphenylphosphine gold(I) chloride [(S)-5]



³¹P NMR (CDCl₃, 200 MHz) spectrum of (S)-(2-(2,2'-diyl hydrogen phosphate-[1,1'-binaphthalen]-3-yl)phenyl) diphenylphosphine gold(I) chloride [(S)-5]


¹H NMR (CDCl₃, 500 MHz) spectrum of (S)-(2-(2,2'-diylchlorogenphosphate-[1,1'-binaphthalen]-3-yl)phenyl) diphenylphosphine gold(I) chloride [SI-1]



¹³C NMR (CDCl₃, 500 MHz) spectrum of (S)-(2-(2,2'-diylchlorogenphosphate-[1,1'-binaphthalen]-3-yl)phenyl) diphenylphosphine gold(I) chloride [SI-1]



³¹P NMR (CDCl₃, 200 MHz) spectrum of (*S*)-(2-(2,2'-diylchlorogenphosphate-[1,1'-binaphthalen]-3-yl)phenyl) diphenylphosphine gold(I) chloride [(*S*)-5b]



¹H NMR (Pyridine, 500 MHz) spectrum of (S)-6



¹H NMR (Pyridine, 500 MHz) spectrum of (S)-6 (zoom 6.8-8.2 ppm)



¹³C NMR (Pyridine, 125 MHz) spectrum of (S)-6



13C NMR (Pyridine, 125 MHz) spectrum of (S)-6 (zoom 120-140 ppm)



³¹P NMR (Pyridine, 200 MHz) spectrum of (S)-6



¹H NMR (CDCl₃, 500 MHz) spectrum of (S)-6



³¹P NMR (CDCl₃, 200 MHz) spectrum of (S)-6



¹H NMR (CDCl₃, 500 MHz) spectrum of (S)-(2-(2,2'-diyl hydrogen phosphate-[1,1'-binaphthalen]-3-yl)phenyl) diphenylphosphine gold(I) bis(trifluoromethanesulfonyl)imide [(S)-7a]



¹³C NMR (CDCl₃, 125 MHz) spectrum of (S)-(2-(2,2'-diyl hydrogen phosphate-[1,1'-binaphthalen]-3-yl)phenyl) diphenylphosphine gold(I) bis(trifluoromethanesulfonyl)imide [(S)-7a]



³¹P NMR (CDCl₃, 200 MHz) spectrum of (*S*)-(2-(2,2'-diyl hydrogen phosphate-[1,1'-binaphthalen]-3-yl)phenyl) diphenylphosphine gold(I) bis(trifluoromethanesulfonyl)imide [(*S*)-7a]



¹H NMR (Pyridine, 500 MHz) spectrum of (S)-(2-(2,2'-diyl hydrogen phosphate-[1,1'-binaphthalen]-3-yl)phenyl) diphenylphosphine gold(I) bis(trifluoromethanesulfonyl)imide [(S)-7a]



³¹P NMR (Pyridine, 200 MHz) spectrum of (S)-(2-(2,2'-diyl hydrogen phosphate-[1,1'-binaphthalen]-3-yl)phenyl) diphenylphosphine gold(I) bis(trifluoromethanesulfonyl)imide [(S)-7a]



¹H NMR (CDCl₃, 500 MHz) spectrum of SI-2



¹³C NMR (CDCl₃, 125 MHz) spectrum of SI-2



³¹P NMR (CDCl₃, 200 MHz) spectrum of SI-2



¹H NMR (CDCl₃, 500 MHz) spectrum of (S)-11a



¹³C NMR (CDCl₃, 125 MHz) spectrum of (S)-11a



³¹P NMR (CDCl₃, 200 MHz) spectrum of (S)-11a



¹H NMR (CDCl₃, 500 MHz) spectrum of (2-bromophenyl)diphenylphosphine oxide



0

13C NMR (CDCl₃, 75 MHz) spectrum of (2-bromophenyl)diphenylphosphine oxide



³¹P NMR (CDCl₃, 200 MHz) spectrum of (2-bromophenyl)diphenylphosphine oxide



¹H NMR (CDCl₃, 500 MHz) spectrum of (R)-3-(2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-1H-indole (10aa)



¹H NMR (CDCl₃, 500 MHz) spectrum of (*R*)-5-methoxy-3-(2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-1H-indole (10ab)



¹H NMR (CDCl₃, 300 MHz) spectrum of (*R*)-5-bromo-3-(2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-1H-indole (10ac)



¹H NMR (CDCl₃, 500 MHz) spectrum of (*R*)-6-methyl-3-(2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-1H-indole (10ad)



¹H NMR (CDCl₃, 500 MHz) spectrum of (*R*)-2-methyl-3-(2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-1H-indole (10ae)



¹H NMR (CDCl₃, 500 MHz) spectrum of (*R*)-1-methyl-3-(2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-indole (10af)



¹H NMR (CDCl₃, 500 MHz) spectrum of (*R*)-1-benzyl-3-(2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-indole (10ag)



¹³C NMR (CDCl₃, 125 MHz) spectrum of (*R*)-1-benzyl-3-(2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-1H-indole (10ag)



¹H NMR (CDCl₃, 500 MHz) spectrum of (S)-3-methyl-2-(2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-indole (14ah)



¹³C NMR (CDCl₃, 125 MHz) spectrum of (S)-3-methyl-2-(2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-1H-indole (14ah)



¹H NMR (CDCl₃, 500 MHz) spectrum of (S)-1,3-dimethyl-2-(2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-indole (14ai)



¹³C NMR (CDCl₃, 125 MHz) spectrum of (S)-1,3-dimethyl-2-(2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-indole (14ai)



¹H NMR (CDCl₃, 500 MHz) spectrum of methyl (*S*)-2-(2-(2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-1H-indol-3-yl)acetate (14aj)



¹³C NMR (CDCl₃, 125 MHz) spectrum of methyl (S)-2-(2-(2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-1H-indol-3-yl)acetate

(14aj)



¹H NMR (CDCl₃, 500 MHz) spectrum of methyl (S)-2-(1-(2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-indol-3-yl)acetate (15aj)



¹³C NMR (CDCl₃, 125 MHz) spectrum of methyl (S)-2-(1-(2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-indol-3-yl)acetate

(15aj)



¹H NMR (CDCl₃, 500 MHz) spectrum of (S)-3-isopropyl-2-(2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-1H-indole (14ak)



¹³C NMR (CDCl₃, 125 MHz) spectrum of (S)-3-isopropyl-2-(2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-1H-indole (14ak)



¹H NMR (CDCl₃, 500 MHz) spectrum of (S)-3-isopropyl-1-(2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-indole (15ak)



¹³C NMR (CDCl₃, 125 MHz) spectrum of (S)-3-isopropyl-1-(2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-indole (15ak)



¹H NMR (CDCl₃, 500 MHz) spectrum of (*R*)-3-(2-(4-methoxyphenyl)-4,5,6,7-tetrahydrobenzofuran-4-yl)-1H-indole (10ba)



¹H NMR (CDCl₃, 500 MHz) spectrum of (*R*)-3-(2-(p-tolyl)-4,5,6,7-tetrahydrobenzofuran-4-yl)-1*H*-indole (10ca)



¹H NMR (CDCl₃, 500 MHz) spectrum of (*R*)-3-(2-(3-methoxyphenyl)-4,5,6,7-tetrahydrobenzofuran-4-yl)-1*H*-indole (10da)



¹³C NMR (CDCl₃, 125 MHz) spectrum of (*R*)-3-(2-(3-methoxyphenyl)-4,5,6,7-tetrahydrobenzofuran-4-yl)-1*H*-indole (10da)



¹H NMR (CDCl₃, 500 MHz) spectrum of (*R*)-3-(2-pentyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-1H-indole (10ea)



¹³C NMR (CDCl₃, 75 MHz) spectrum of (*R*)-3-(2-pentyl-4,5,6,7-tetrahydrobenzofuran-4-yl)-1H-indole (10ea)



¹H NMR (CDCl₃, 500 MHz) spectrum of (*R*)-3-(2-phenyl-5,6-dihydro-4H-cyclopenta[b]furan-4-yl)-1H-indole (10fa)



¹³C NMR (CDCl₃, 125 MHz) spectrum of (*R*)-3-(2-phenyl-5,6-dihydro-4H-cyclopenta[b]furan-4-yl)-1H-indole (10fa)



¹H NMR (CDCl₃, 500 MHz) spectrum of (*R*)-3-(2-phenyl-5,6,7,8-tetrahydro-4H-cyclohepta[b]furan-4-yl)-1H-indole (10ga)



¹³C NMR (CDCl₃, 125 MHz) spectrum of (*R*)-3-(2-phenyl-5,6,7,8-tetrahydro-4H-cyclohepta[b]furan-4-yl)-1H-indole (10ga)



¹H NMR (CDCl₃, 500 MHz) spectrum of benzyl (S)-(2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)carbamate (16a)



¹H NMR (CDCl₃, 500 MHz) spectrum of (S)-4-methyl-N-(2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)benzenesulfonamide

(16b)



¹H NMR (CDCl₃, 500 MHz) spectrum of (S)-N,2-diphenyl-4,5,6,7-tetrahydrobenzofuran-4-amine (16c)



¹H NMR (CDCl₃, 500 MHz) spectrum of (S)-4-phenoxy-2-phenyl-4,5,6,7-tetrahydrobenzofuran (16d)



¹H NMR (CDCl₃, 500 MHz) spectrum of (S)-2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-ol (16e)



¹H NMR (CDCl₃, 500 MHz) spectrum of (*S*)-2-phenyl-4-(((*R*)-2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)oxy)-4,5,6,7-tetrahydrobenzofuran (**16eb**)



¹³C NMR (CDCl₃, 125 MHz) spectrum of

 $(S) - 2 - phenyl - 4 - (((R) - 2 - phenyl - 4, 5, 6, 7 - tetrahydrobenzofuran - 4 - yl)oxy) - 4, 5, 6, 7 - tetrahydrobenzofuran ({\bf 16eb}) - 2 - phenyl - 4, 5, 6, 7 - tetrahydrobenzofuran - 4 - yl)oxy) - 4, 5, 6, 7 - tetrahydrobenzofuran ({\bf 16eb}) - 2 - phenyl - 4, 5, 6, 7 - tetrahydrobenzofuran - 4 - yl)oxy) - 4, 5, 6, 7 - tetrahydrobenzofuran ({\bf 16eb}) - 2 - phenyl - 4, 5, 6, 7 - tetrahydrobenzofuran - 4 - yl)oxy) - 4, 5, 6, 7 - tetrahydrobenzofuran ({\bf 16eb}) - 2 - phenyl - 4, 5, 6, 7 - tetrahydrobenzofuran - 4 - yl)oxy) - 4, 5, 6, 7 - tetrahydrobenzofuran ({\bf 16eb}) - 2 - phenyl - 4, 5, 6, 7 - tetrahydrobenzofuran - 4 - yl)oxy) - 4, 5, 6, 7 - tetrahydrobenzofuran ({\bf 16eb}) - 2 - phenyl - 4, 5, 6, 7 - tetrahydrobenzofuran - 4 - yl)oxy) - 4, 5, 6, 7 - tetrahydrobenzofuran ({\bf 16eb}) - 2 - phenyl - 4, 5, 6, 7 - tetrahydrobenzofuran - 4 - yl)oxy) - 4, 5, 6, 7 - tetrahydrobenzofuran - 4 - yl)oxy) - 4, 5, 6, 7 - tetrahydrobenzofuran - 4 - yl)oxy) - 4, 5, 6, 7 - tetrahydrobenzofuran - 4 - yl)oxy) - 4, 5, 6, 7 - tetrahydrobenzofuran - 4 - yl)oxy) - 4, 5, 6, 7 - tetrahydrobenzofuran - 4 - yl)oxy) - 4, 5, 6, 7 - tetrahydrobenzofuran - 4 - yl)oxy) - 4, 5, 6, 7 - tetrahydrobenzofuran - 4 - yl)oxy) - 4, 5, 6, 7 - tetrahydrobenzofuran - 4 - yl)oxy) - 4, 5, 6, 7 - tetrahydrobenzofuran - 4 - yl)oxy - 4, 5, 6, 7 - tetrahydrobenzofuran - 4 - yl)oxy - 4, 5, 6, 7 - tetrahydrobenzofuran - 4 - yl)oxy - 4, 5, 6, 7 - tetrahydrobenzofuran - 4 - yl)oxy - 4, 5, 6, 7 - tetrahydrobenzofuran - 4 - yl)oxy - 4, 5, 6, 7 - tetrahydrobenzofuran - 4 - yl)oxy - 4, 5, 6, 7 - tetrahydrobenzofuran - 4 - yl)oxy - 4, 5, 6, 7 - tetrahydrobenzofuran - 4 - yl)oxy - 4, 5, 6, 7 - tetrahydrobenzofuran - 4 - yl)oxy - 4, 5, 6, 7 - tetrahydrobenzofuran - 4 - yl)oxy - 4, 5, 6, 7 - tetrahydrobenzofuran - 4 - yl)oxy - 4, 5, 6, 7 - tetrahydrobenzofuran - 4 - yl)oxy - 4, 5, 6, 7 - tetrahydrobenzofuran - 4 - yl)oxy - 4, 5, 7 - tetrahydrobenzofuran - 4 - yl)oxy - 4, 5, 7 - tetrahydrobenzofuran - 4 - yl)oxy - 4, 5, 7 - tetrahydrobenzofuran - 4 - yl)oxy - 4, 5,$



¹H NMR (CDCl₃, 500 MHz) spectrum of (4R,4'R)-4,4'-oxybis(2-phenyl-4,5,6,7-tetrahydrobenzofuran) (16ec)



¹³C NMR (CDCl₃, 125 MHz) spectrum of (4R,4'R)-4,4'-oxybis(2-phenyl-4,5,6,7-tetrahydrobenzofuran) (16ec)



¹H NMR (CDCl₃, 300 MHz) spectrum of (*R*)-2-(2-phenyl-4,5,6,7-tetrahydrobenzofuran-4-yl)cyclohexane-1,3-dione (16f)